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ABSTRACT 
 
Highly active antiretroviral treatment (HAART) has transformed the state of 
human immunodeficiency virus (HIV) from acute to chronic. As a result, the long-term 
effect of HAART has caused weight gain among HIV-infected individuals, leading to an 
increased prevalence of overweight and obesity. Increased Body Mass Index (BMI) has 
been associated with adverse health outcomes in non-HIV and HIV populations, yet 
among HIV-infected individuals, a higher BMI at diagnosis offers a slower progression 
from HIV to AIDS. Pre-HAART, studies reported that obese HIV-infected individuals 
have higher increases in CD4 count over time. However post-HAART, some report that 
overweight HIV-infected individuals with a higher BMI experience increased CD4 
counts. In addition, HIV-infected treated individuals are now experiencing cardiovascular 
disease outcomes. Therefore, additional research is needed to support current evidence.  
Given that our study population consists of individuals from South Carolina, a state with 
a high prevalence of HIV and obesity, it is beneficial to explore the relationship between 
BMI at diagnosis and markers for HIV progression and cardiovascular disease risk. This 
cohort study consisted of 396 HIV-infected adults from the Ryan White Clinic in SC. The 
objectives of this study were to evaluate the relationship between BMI at diagnosis and 
CD4 count over time, to evaluate this relationship by gender, and to evaluate the 
relationship between BMI at diagnosis and cardiovascular disease risk markers (high-
density lipoprotein(HDL), low-density lipoprotein (LD), systolic blood pressure (SBP), 
diastolic blood pressure (DBP), and fasting blood glucose).  
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CHAPTER 1 
 
INTRODUCTION 
In HIV infection, CD4 count is used to determine treatment and monitor 
progression of HIV.1 2 3 It also serves as the most important prognostic factor that 
correlates the most with disease progression. Furthermore, CD4 count also is associated 
with the risk of cardiovascular disease among HIV patients.4 5 6 While the relationship 
between disease progression and CD4 has been proven, other factors such as HIV-RNA 
viral load, mode of transmission, age, gender and race also have been determined to be 
associated with disease progression.7 8 9 10 11 12 13 14 15   Recent evidence suggests that 
nutritional status also impacts disease progression and the development of complications 
but this has not been extensively researched.  
Body mass index (BMI) is an anthropometric indicator computed from height and 
weight and has been used to predict survival in non-HIV patients.7 17 18 Those considered 
to be underweight (BMI<18.0) or obese (BMI≥30) are at higher risk of acquiring 
infections such as pneumonia, bacteraemia and lower respiratory infections.18 A 
systematic review reported that obese individuals with infections had worst outcomes 
compared to the other BMI categories.18 It is well documented that obesity leads to 
adverse health outcomes such as cardiovascular disease, diabetes, cancer and mortality.19 
Among HIV patients, those obese tend to have higher CD4 levels and lower HIV-RNA 
viral loads. A possible explanation of this effect is that the increased levels of leptin in 
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obese individuals, increases T-cell proliferation.20 Since viral load has an inverse 
relationship with CD4 T-cells, it is possible that as CD4 count increases, viral load will 
decrease as a response to the relationship between leptin and CD4 T-cells. Those 
considered being underweight and malnutrioned at the time of starting treatment were 
associated with increased risk of survival. 20 Given obesity’s effect on the immune 
system, it is logical to determine the association of BMI on progression of HIV. As the 
data needed to compute BMI are relatively easy and inexpensive to collect, it can be 
efficient to use BMI as an indicator to predict HIV progression. 
 Previous research on BMI and HIV disease progression has produced mixed 
results. Obese HIV patients during the pre-highly active antiretroviral therapy (HAART) 
era were seen to have a better survival rate or slower progression to AIDS compared to 
normal weight HIV patients as well as those who experienced the "wasting syndrome."21 
Studies have showed that HIV individuals who were obese at diagnosis have a decreased 
risk of disease progression and better survival compared to other BMI categories.7 17 21 22 
23 24 25 Obese HIV individuals at diagnosis also reportedly have higher CD4 counts and 
lower HIV-RNA viral loads over-time. HIV individuals with increasing BMIs over-time 
also have been associated with a decreased risk of disease progression. However during 
the era of HAART, recent studies report that the protective effect of obesity may no 
longer exist. It was reported that obese HIV patients now experience smaller increases in 
CD4, concluding that obesity may actually provide more harm to HIV patients. 26 27 There 
is limited evidence in this area of HIV, particularly in the era of HAART, and this study 
will provide a longitudinal analysis of this association. 
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 As a result of the development of metabolic risk factors such as obesity, among 
HIV patients, the risk of cardiovascular disease (CVD) has increased. 21 After the 
initiation of HAART, more HIV patients became obese, leading to an increased chance of 
developing cardiovascular outcomes. 21 One study reported that BMI was useful in 
predicting CVD risk among their HIV population.28 Using hsCRP, an established 
predictor of future coronary events, it was discovered that higher hsCRP levels were 
associated with higher BMIs, higher low-density lipoprotein (LDL) and triglyceride (TG) 
levels, and lower high-density lipoprotein (HDL) levels. However, they were limited due 
to the small sample size.  Given the increased risk of CVD outcomes in non-HIV obese 
individuals, it is important to study this association among obese HIV individuals. One 
serum marker used to determine risk of CVD is cholesterol. In non-HIV patients, lower 
HDL levels and higher LDL and TG levels are associated with increased risk. 29 Among 
HIV patients, studies report that lower CD4 counts and higher HIV-RNA viral load at 
diagnosis are both associated with lower HDL levels and higher LDL and TG levels.4 6 
Among HAART naïve HIV patients, higher BMI was associated with higher total 
cholesterol. However, this association is higher among HAART treated HIV patients. 4 6  
It is unclear whether BMI was measured at diagnosis or followed over-time.  
To our knowledge, only five cohort studies (Boston, France, Miami, Nashville, 
and West Africa) have been conducted to determine how well baseline BMI predicts HIV 
disease progression.17 22 23 24 25 These studies populations consisted of HIV individuals 
who were from sub-Saharan Africa17, drug abusers22, public hospitals patients from 
France23, only women.24, and those from an outpatient clinic in Nashville, TN.25  Two of 
the studies used HIV-naïve patients as controls 22 24, while the other studies consisted of 
 4 
 
 
only HIV patients.17 23 25  These studies mainly focused on the association of BMI and 
mortality and determined that BMI was a strong predictor of survival among HIV. While 
these studies predicted survival and used certain AIDS defining events (e.g. first CD4 cell 
count <200 cells/mm3) as outcomes, our study will focus on the longitudinal analysis of a 
marker of HIV progression (i.e. CD4 count) as our outcome.  Some studies have used 
BMI as a time-dependent variable when determining the association with markers of 
disease progression.20 21 22 24 25 30 31 32   However, this study will observe between disease 
progression and BMI at diagnosis. It is important to determine whether BMI at diagnosis 
has an association with markers of cardiovascular risk, as previous results have been 
inconclusive.34 35 36 37 38 39 40 41 42 Recently, Koethe et al. discovered that patients classified 
as overweight may promote optimal immune reconstitution (i.e. higher levels of CD4) 
within 12 months of diagnosis once on HAART compared to those obese.25 Therefore, it 
will be interesting to see if those results are repeated in the current study.   
Data regarding the prognostic use of BMI in HIV patients are limited. The current 
study will help to clarify the prospective association between obesity and disease 
progression among HIV patients and, and the development of cardiovascular disease risk 
markers in this population. The results of this study will help clinicians gain a clearer risk 
profile of the HIV patient for more effective monitoring. The specific aims of this 
proposal are as followed: 
Aim 1:  To determine the association between BMI at diagnosis and a marker of disease 
progression (CD4 T cell count) over time. 
Research Question 1.1:  Is there a difference in mean CD4 between BMI 
categories?  
Research Question 1.2:  Do HIV patients who are obese at baseline have a 
slower progression of HIV (Higher CD4 T cell count) over time compared to 
those in the normal BMI categories? 
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Aim 2:  To determine whether the association between BMI at diagnosis and a marker of 
disease progression (CD4 T cell count) over time differ by gender. 
Research Question 2.1:  Does the association between baseline BMI and disease 
progression over time (CD4 T cell count) vary by gender? 
 
Aim 3:  To determine the association between BMI at diagnosis and markers of 
cardiovascular disease risk (fasting blood glucose, HDL, LDL, SBP, and DBP) over time. 
Research Question 3.1:  Is there a difference in mean fasting blood glucose, 
mean HDL, mean LDL, mean SBP, and mean DBP between BMI categories?  
Research Question 3.2:  Do normal weight HIV patients at baseline have lower 
levels of these cardiovascular risk markers over time compared to obese HIV-
patients? 
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CHAPTER 2 
LITERATURE REVIEW 
2.1 What is HIV? 
The human immunodeficiency virus (HIV) is a sexually transmitted disease that 
leads to acquired immune deficiency syndrome (AIDS), the later stage of the HIV 
infection.1 There are two different types of HIV are HIV-1 and HIV-2. In the United 
States (U.S.), HIV is primarily referred to only HIV-1.1 HIV is spread by contact with 
infected blood through unprotected sex, the sharing of needles, from mother to child 
during pregnancy, childbirth, or breastfeeding.1  HIV destroys specific blood cells called 
CD4+ T cells, also known as “helper cells”, which are essential in helping a person’s 
body fight diseases.1 Once the immune system is weakened, the body’s ability to fight 
organisms is diminished, leading to a greater chance of developing AIDS.  
Several complications are related to the HIV infection. These include 
opportunistic infections such as tuberculosis, candidiasis, pneumonia, toxoplasmosis, 
kaposi’s sarcoma, herpes simplex, and tuberculosis.1 Other complications include 
different forms of cancer, lipodystrophy as well as chronic wasting. These infections can 
occur at different stages of HIV. People without HIV are also at risk of acquiring these 
infections. However, these infections occur at a higher rate and it takes longer to recover 
in those with HIV.1   
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2.2 Epidemiology of HIV/AIDS 
2.2a Global 
 The number of people living with HIV worldwide has increased since its 
discovery. The number of people living with HIV increased from roughly 9 million 
people in 1990 to a total of 33.3 million people in 2009, with approximately 1.8 million 
deaths due to AIDS.43  The majority of people living with HIV reside in Sub-Saharan 
Africa (68%), South and South-East Asia (12%), North America (5%), and Central and 
South America (4%), respectively. 43 A total of 2.6 million people were newly infected 
with HIV worldwide in 2009, with the majority being adults (85%). 43  The Joint United 
Nations Programme on HIV/AIDS  reported that over 7000 new HIV infections occurred 
per day in 2009, with roughly 97% of those infections being mostly women (51%) and  
occurring in low and middle income countries.44  
2.2b United States (U.S.) 
 The prevalence of HIV among people in the US was estimated to be 
approximately 1.1 million persons in 2006, with approximately 21% being undiagnosed. 1 
The Centers for Disease Control and Prevention (CDC) reported that approximately 
56,300 people were newly infected with HIV in 2006. 1 The majority of those new HIV 
cases (53%) occurred in men who have sex with men (MSM). 1 MSM account for nearly 
half of people living with HIV (48%), while heterosexuals account for only 25%.26 
African Americans account for 46% of people living with HIV in the US as well as 45% 
of new HIV infections. 1 The HIV incidence rate for African American men and women 
was 7 times higher than their Caucasian counterparts. 1 Hispanics/Latinos represent 15% 
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of the population but account for an estimated 17% of people living with HIV and 17% of 
new infections. 1 
2.2c South Carolina (SC) 
 In their 2007 surveillance report, the CDC reported that the Deep South (i.e. 
Alabama, Florida, Georgia, Mississippi, Louisiana, North Carolina, and South Carolina) 
were disproportionately affected by the HIV/AIDS epidemic. 1 In 2008, South Carolina 
was ranked 10th in the US in AIDS cases, with a rate of 15.5 per 100,000 persons. 1 South 
Carolina also ranked 7th in AIDS cases among females in the US, with a rate of 13.0 per 
100,000. 1 The epidemic continues to increase in South Carolina with an average of 65 
cases of HIV infections reported each month in 2009. 1 Furthermore, South Carolina has 
experienced a 52% increase in people living with HIV/AIDS from 1999 to 2009. 1 People 
who live with HIV in South Carolina are mostly men (69%), African American (73%), 
aged 20-44 (42%) and MSM (44%).1 45   
2.3 Predictors of progression in HIV 
HIV is broken down into four distinct stages:  primary infection, clinically 
asymptomatic stage, symptomatic HIV infection and progression from HIV to AIDS. 1 
Stage one, the primary infection stage, lasts for a few weeks and diagnosis is frequently 
missed. During this stage, the immune system begins to respond to the HIV in the blood, 
producing HIV antibodies and cytotoxic lymphocytes, which is known as seroconversion. 
Stage two represents the clinically asymptomatic stage and generally lasts for an average 
of ten years. HIV antibodies are detectable in the blood and diagnosis is usually evident 
during this stage. Stage three is the symptomatic HIV infection stage whereby the 
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immune system has become severely damaged. HIV also has mutated allowing for 
further destruction of the CD4 T-helper cells, which are needed to fight infection. 
Furthermore, symptomatic HIV is usually caused by the opportunistic infections 
described earlier. Finally, Stage four represents progression to AIDS which is caused by 
the low count of CD4 T-helper cells and the increased number of severe opportunistic 
infections.  
Throughout HIV, there are several determinants that can be used to determine the 
progression HIV.7  These determinants include immunological factors such as CD4+ T 
cells and CD8 T-lymphocytes, virological factor such as HIV-RNA viral load, and other 
factors such as age, gender, mode of transmission and body mass index. An 
understanding of these factors is essential in guiding patient management and treatment. 
While some of these prognostic factors are typically used to initiate treatment, track the 
progression of HIV infection (e.g. CD4 count and HIV-RNA viral load) and monitor 
response to treatment, others (e.g. BMI) are not used as much and could also possibly 
assist in tracking the progression of the disease and providing the best methods in treating 
each HIV patient. This could ultimately lead to a greater chance of survival.  
2.3a CD4+ T-cells 
 Known as the most significant predictor of disease progression and survival in 
HIV patients, CD4 T-cell count takes precedent over any other predictors that are used 
when treatment guidelines are recommended.2 3 7 CD4 T-cells are essential to the immune 
system as they serve as signals that activate the immune’s response to organisms such as 
viruses and bacteria. HIV attaches to and infects the CD4 T-cells. Over the course of 
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HIV, CD4 T-cell count begins to decline. As a result, it is important that CD4 T-cell 
counts are maintained within the normal range, which is 500-1000 cells/mm3. Treatment 
is generally recommended when a HIV patient’s CD4 T-cell is ≤350 cells/mm3 and when 
patients are in Stage 3 and 4 of the disease, irrespective of CD4 count.1 3 4 Once the cell 
count is less than 200 cells/mm3, the patient’s immune system is severely weakened. This 
leads to a greater risk for developing HIV-related complications and opportunistic 
infections, including progression to AIDS.  
 Many studies have shown that CD4 count is highly associated with HIV 
progression.2 7 8 46 47  The CASCADE collaboration reported that lower CD4 counts were 
associated with a greater risk of disease progression, with the greatest risk occurring as 
CD4 counts fall below 200 cells/mm3.48 This remains true when stratified by age. Van 
Leth et al. determined that baseline CD4 T-cell count is predictive of virological failure.46 
They showed that CD4 T-cell counts below 200 cells/mm3 at time of HAART initiation 
are associated with an increasingly worse prognosis.47  
2.3b CD8 T-cells 
 CD8 T-cells, also called cytotoxic T-lymphocytes, are white blood cells that find 
and destroy infected cells in the body.1 7 In the case of HIV, CD8 T-cells are activated by 
CD4 T cells. It is thought that the anti-HIV specific CD8 T-cells are responsible for the 
demise of the infected CD4 T-cells, further increasing in response to ongoing viral 
replication. Evidence suggests that low absolute numbers of CD8 T-cell count correlate 
with poor survival outcomes in HIV patients.7   
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2.3c HIV-RNA viral load 
 HIV-RNA viral load is the second most important marker used to determine 
response to treatment.3 7 In most HIV patients, HIV-RNA viral load has an inverse 
relationship with CD4 T-cell count. Higher HIV-RNA viral loads are correlated with a 
rapid decline of CD4 T-cells. 3 7  A four-fold increase in the risk of AIDS can be detected 
when HIV-RNA viral load is between 3000 copies/mL and 300,000 copies/mL, which 
also is seen when stratified by age groups.7  In addition, there is an increase in risk of 
disease progression in HIV patients with HIV-RNA viral loads greater than 100,000 
copies/mL across all age and CD4 T-cell strata. 7  
 Higher HIV-RNA viral loads at diagnosis have been associated with faster CD4 
T-cell decline over the first two years of infection.2 7 Some evidence has suggested that 
HIV-RNA viral load serves as a better marker of disease progression when measured at 
later times than at diagnosis.3 7 However, HIV-RNA viral load at diagnosis assists in 
providing treatment to HIV patients earlier. Van Leth et al. reported that treatment 
response was strongly related to HIV-RNA viral load at diagnosis, with HIV patients 
whose HIV-RNA viral loads that were greater than 100,000 copies/mL at diagnosis 
experiencing more virological failure after 48 weeks of treatment.46 According to recent 
treatment guidelines, HIV-RNA viral load is only used to detect response to treatment 
and not to monitor progression of HIV.3  
2.3d Age 
 Research has shown that as HIV patients get older, their risk of AIDS increases.7 
Age at seroconversion has been found to have significant impact on the future 
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progression of HIV. Previous studies found an age effect correlating with CD4 count and 
HIV-RNA viral load across all exposure categories.8 49 Some have suggested that since 
older age is associated with lower CD4 counts at similar time from seroconversion, it 
may explain the relationship between age and HIV progression.7 8 However, when HIV 
patients are on HAART, the age effect at seroconversion is attenuated.     
2.3e Gender 
 Mixed results have been reported on the relationship between gender and HIV 
progression. Some studies report that gender differences in HIV disease progression has 
become larger and statistically significant in the era of HAART.7 8 9 13 14 15 16 Women tend 
to have a higher HIV-RNA viral load at diagnosis compared to men, while HIV-RNA 
viral load over-time has reportedly varied.7 9 10 Women also reportedly had an increased 
risk of death even after adjustment for HAART use. 7 9 10 Low levels of CD4 T-cells (<50 
cells/mm3 ) were found to be associated with higher HIV-RNA viral loads in women than 
in men within the same CD4 count.9 Conversely, at higher CD4 T-cell levels (>350 
cells/mm3), mean HIV-RNA viral load has been noted to be lower in women compared to 
men in the same CD4 stratum.8 Despite the variation in HIV-RNA viral load, disease 
progression has not been seen to differ between genders for CD4.7 11 One study reported 
that disease progression was similar between genders. 11 Currently, there is no sex-
specific treatment guideline for the initiation of treatment.3  
2.3f Race 
 Research that has focused on the relationship between race and HIV progression 
has discovered that race mainly does not have an impact on the progression of HIV, 
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which is independent of confounders such as psychosocial factors, access to care and 
genetically driven response to therapy.7 However, three studies discovered a difference 
between race and HIV disease progression.12 14 16 Lemly et al. reported that the African 
Americans had an increased risk of death compared to Caucasians.14 However, this 
association was no longer seen after adjustment for HAART use. Smith et al. reported 
that HIV-RNA viral load was discordantly low in African Americans compared to 
Caucasians stratified for CD4 count.12 Finally, Meditz et al. reported that Non-Caucasian 
women were most likely to experience an HIV/AIDS related event compared to others (p 
= .035), even after adjustment for intravenous drug and HAART use.16  
2.3g Mode of Transmission 
 Contradictory results have been reported on the effect of mode of transmission on 
HIV disease progression. An earlier study reported that homosexuals had a significantly 
faster progression compared to heterosexuals.50 However, a recent study found no 
difference in disease progression between the different modes of HIV transmission.51 It is 
important to note that injected drug users do have other-cause mortalities, which could 
confound the results of a study. This was seen in the CASCADE collaboration study 
where they determined in the post-HAART era, homosexual and heterosexual risk groups 
have a reduction in mortality, while no change was seen among injected drug users.48 The 
higher risk in injected drug users can be due to lack of adherence to treatment and lack of 
access to treatment.  
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2.3h Body Mass Index (BMI) 
 Body mass index is a simple predictor that has been recently used to determine 
progression of HIV.7 The association between BMI and HIV progression is important for 
two reasons. First, the “wasting syndrome”, which is involuntary loss of more than 10% 
of body weight including more than 30 days of diarrhea, weakness, or fever, is 
considered an AIDS defining illness according to the CDC classification of disease.1 
Secondly, the simplicity of measuring BMI allows it to serve as a highly useful marker 
for the initiation of treatment in resource-limited countries.  Past research has shown that 
long-term monitoring of BMI is predictive of disease progression.7 20 21 22 23 24 25 A rapid 
decline in BMI among HIV patients has been shown six months preceding the diagnosis 
of AIDS.7 24 Those considered underweight at diagnosis have been shown to be predictive 
of increased mortality, even in racially diverse cohorts.7 17 One study discovered that a 
BMI < 17 kg/m2 six months after initiation of treatment has been associated with a two-
fold increase in risk of death.6 Furthermore, a BMI < 18.5 kg/m2 shows similar utility to 
CD4 count and HIV-RNA viral load based guidelines for the initiation of treatment. 7 
Given these associations between BMI and survival among HIV patients, as well as 
BMI’s correlation with infection in non-HIV patients18, BMI may prove to be a valuable 
predictor for disease progression in HIV patients.  
2.4  Predictors of cardiovascular related outcomes among HIV patients 
During the early years of HIV/AIDS, the “wasting syndrome” was once the 
hallmark of HIV/AIDS.1 21 Pronounced loss of weight, lean body mass and fat mass were 
attributed to an array of factors including opportunistic infection, living below the 
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poverty level, low CD4+ cell count and high viral load.1 Today, HAART has transformed 
HIV disease into a chronic illness, which has caused incidence of wasting to decrease and 
the rates of obesity to increase.  
People living with HIV are gaining weight and beginning to approach weight 
levels seen in the general U.S. population. Approximately two out of every three adults 
are overweight (i.e. BMI = 25-29.9) and one in every four adults are obese (i.e. BMI≥30) 
in the US.21 Six states, including South Carolina (30.1%) had a prevalence of obesity 
equal to or greater than 30% in the general population.19 Some studies have reported a 
lower prevalence of obesity among HIV-infected populations versus the general 
population,52 53 whereas others have reported a higher prevalence .24 54 Although the 
effect of HAART in causing obesity in HIV-infected patients  may quantify the relatively 
slower progression to AIDS and provides the survival advantage afforded by elevated 
BMI,24 certain problems have arose that has caused researchers question the mechanistic 
role of HAART.  
Shortly after the introduction of HAART, several new metabolic abnormalities 
were reported and linked to its use.55 Overweight and obesity are considered to be 
primarily responsible for the rising prevalence of these abnormalities. When taken 
together, these abnormalities form what is called the metabolic syndrome, which is seen 
in both non-HIV and HIV patients. Components of metabolic syndrome typically include 
abdominal obesity, hyperlipidemia, hypertension and diabetes.56  
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2.4a  Cholesterol  
 Cholesterol is a waxy, fat-like substance that occurs naturally in the body.57 
Cholesterol is needed for the body to work properly, but if too much is in the blood, it can 
lead to plaque build-up in the arteries. This can lead to increased risk of developing heart 
disease, stroke, and other cardiovascular disease outcomes.  
There are three types of cholesterol:  Total Cholesterol (all cholesterol combined), 
High density lipoprotein (HDL) cholesterol (known as the good cholesterol), and Low 
density lipoprotein (LDL) cholesterol (known as the bad cholesterol). 57  Low levels of 
HDL combined with high levels of LDL and triglycerides indicate high cholesterol or 
what is better known as hyperlipidemia. Generally, high cholesterol levels are caused by 
unhealthy lifestyles, being overweight as well as certain medications such as diuretics 
and beta-blockers. 57  Approximately one in every six adults (~16%) of the U.S. adult 
population have high total cholesterol (> 240 mg/dL), with Hispanic men and Caucasian 
women displaying the highest levels of total cholesterol. 57  People with high total 
cholesterol have about twice the risk of heart disease as people with optimal levels. 57  
Furthermore, certain conditions such as hypertension and diabetes can be exacerbated by 
high levels of cholesterol in the blood.  
 The amount of people affected by cholesterol among the HIV population seems to 
mirror the cholesterol levels among the general population. Low levels of HDL have been 
reported among HIV patients, and are associated with hypertriglyceridemia (i.e. high 
blood levels of triglycerides).5 33 34 Furthermore, low CD4 T-cell counts and high levels 
of HIV-RNA viral load also are associated with low levels of HDL. 6 33 34  In 2006, El-
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Sadr et al. compared cholesterol levels among obese HIV patients and non-obese HIV 
patients and determined that a higher BMI was associated with higher lipid levels.6 Some 
research has suggested that the high levels of cholesterol in HIV patients is as a result of 
the HIV medication.6 34 Additional research is needed to study the association between 
cholesterol and HIV progression.  
2.4b  Hypertension 
 Blood pressure is the force of blood against your artery walls as it circulates 
throughout your body.58 Blood pressure is measured using two numbers. The first number 
is the systolic measurement and it represents the pressure in your blood vessels when 
your heart beats. The second number is the diastolic measurement and it represents the 
pressure in your vessels when your heart rests between beats. A normal blood pressure 
reading is 120/80 mmHg, while someone with high blood pressure (hypertension) will 
have a reading ≥ 140/90 mmHg. 58 Blood pressure tends to rise with age, but can be 
controlled by following a healthy lifestyle. 58 Hypertension can lead to increased risk of 
developing heart disease and stroke, which are the first and third leading causes of death 
in the U.S. 50 About one out of every three adults (~31%) in the U.S. has hypertension. 
Males, African Americans, and those of older age are more likely to develop 
hypertension. 58    
 Among the HIV population, traditional risk factors are also associated with 
hypertension.35 36 These factors include older age, overweight/obesity, family history of 
hypertension, and increased levels of triglycerides. CD4 counts below 200 cells/mm3 
show a tendency to be protective against hypertension in a univariate analysis, but this 
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association was no longer seen when included in the full model.35 Most studies report that 
the prevalence of hypertension among HIV patients is anywhere between 25%-35%, 
which is very similar to the proportion of adults affected in the general population.35 36 37 
38 39  Some studies have raised the possibility that HAART may induce hypertension 
through hardening of the vessel walls,36 39 however others report minimal effects.37 38  
2.4c  Diabetes 
 Diabetes is a disease in which blood glucose levels are above normal.59 Your 
body either does not make enough insulin or cannot use its own insulin as well as it 
should, and can cause sugar build-up in the blood. Several risk factors are associated with 
getting diabetes such as genetics, poor diet, overweight/obesity, and the environment.59 
Tests such as the fasting blood glucose test, hemoglobin A1C, and oral glucose tolerance 
test are all used to determine diagnosis of diabetes. 59 However, it does require that two 
consecutive tests confirm this diagnosis.60 A fasting blood glucose test with values higher 
than 126 mg/dL, a hemoglobin A1C test with values 6.5% or higher, and an oral glucose 
tolerance test with values higher than 200 mg/dL all constitutes a positive diagnosis of 
diabetes. 59 60 Risk factors for diabetes include older age, family history of diabetes, 
physical inactivity, and race/ethnicity. 59 Diabetes can lead to heart disease, blindness, 
kidney failure, and lower-extremity amputations. It is the seventh leading cause of death, 
and affects more than 20 million Americans. 59  
 In HIV patients, mostly BMI, family history of diabetes, and certain HIV/AIDS 
medications are associated with diagnosis of diabetes.40 41 The prevalence of diabetes 
among HIV patients has been reported to be between 1%-10%.40 41  One study reported 
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that incidence of diabetes increases with cumulative exposure to HAART.41 The HIV 
population also tends to have a greater chance for the development of complications due 
to diabetes when compared to HIV naïve patients.42 Certain opportunistic infections, such 
as cytomegalovirus retinitis, can increase the chance of developing diabetic retinopathy in 
HIV patients. 42 Therefore, it may be possible that control of such opportunistic infections 
may help in reducing the diabetic complications seen in HIV patients.  
2.5 Public Health Importance  
 Taken together, studying factors that influence progression of HIV is imperative. 
Non-traditional factors such as BMI may be useful to clinicians in providing the best 
clinical plan for each individual HIV patient. Furthermore, additional research on the risk 
of cardiovascular disease in HIV patients is needed. The populations sampled in past 
research have not provided the best population for studying this relationship. The 
population that will be sampled for our study will offer an array of HIV patients that will 
allow us to determine whether an association exists in the era of HAART.  
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CHAPTER 3 
METHODS 
3.1 Study design 
The design of this study will be a retrospective cohort, determining how BMI 
(exposure) is associated with markers of HIV progression and cardiovascular disease risk. 
The marker for HIV progression includes CD4 T-cell count, while the markers of 
cardiovascular disease risk include fasting blood glucose, HDL, LDL, SBP and DBP. The 
inclusion criteria will be HIV positive individuals who are at least 18 years of age, with 
BMI being measured within three months of HIV diagnosis, and those with at least 1 
follow-up after BMI was recorded at diagnosis. They will be grouped by their BMI status 
into the following four categories:  underweight, normal, overweight and obese. Both the 
values and the measurement dates of CD4 T-cells, HIV-RNA viral load, fasting blood 
glucose, HDL, LDL, SBP and DBP will be collected.  
3.2 Study Population 
Setting:  Medical records from the Ryan White HIV/AIDS Clinic in Columbia, 
SC will be reviewed to collect data for this study. The Ryan White HIV/AIDS program is 
a federally funded program that reaches more than 529,000 people a year in the United 
States.35 It funds primary care and support services to low-income and underserved 
individuals and families living with HIV disease. 35 In 2007, the Ryan White program 
served 11,554 clients in South Carolina, with 100% of those clients being affected by 
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HIV. The majority of the clients served in the Ryan White Clinic in South Carolina are 
male (60%), African American (73%), and aged 25-44 (50.7%).35  
Time Period:  Since this study looks to determine the associations after HAART 
was introduced in 1996, we will include individuals who were newly diagnosed between 
January 1, 1997 and December 31, 2010, which is a total of 14 years.  
3.3 Data Analysis 
AIM 1:  To determine the association between BMI at diagnosis and a marker of 
disease progression (CD4 T cell count) over time. 
In order to determine the association between baseline BMI and markers of HIV, 
the following formula will be used to calculate BMI:  (weight in lbs. * 703)/(height in 
inches2). Descriptive analyses will be conducted. Statistical analyses will utilize 
Pearson’s χ2, Fisher’s exact, or Kruskal-Wallis tests for categorical variables and t-test for 
continuous variables. A change between two test results is considered significant if it is a 
30% change in absolute CD4 count or 3 percentage point change in CD4 percentage. A 
mixed regression analysis will be conducted to determine whether the mean values of the 
marker of HIV progression (CD4 count) are different over-time between BMI categories, 
after adjusting for the following confounding variables: race, gender, age, marital status, 
smoking, alcohol use, drug use, insurance, case manager, education, mode of 
transmission delayed entry into care, and HAART use. These variables were chosen due 
to their association between both BMI and the HIV disease. Tukey’s multiple 
comparisons test will be used to determine which BMI categories’ mean values, if any, 
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are different from each other. A loess fitting will be used if the data appears to be non-
linear. Graphical comparisons will also be performed.   
Table 3.1:  Independent variables for AIM 1  
Variables Date Levels  Categories 
HIV seroconversion/diagnosis Baseline Date Date 
Race/Ethnicity Baseline 4 White (ref) 
Black 
Hispanic 
Other 
Gender Baseline 2 Male (ref) 
Female 
Age Baseline 5 <20 
21-29 (ref) 
30-39 
40-49 
50-59 
≥60 
Marital Status Baseline 4 Single (ref) 
Married 
Divorced 
Widowed 
Smoking Status Baseline 2 No (ref) 
Yes 
Alcohol Use Baseline 2 No (ref) 
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Yes 
Drug Use Baseline 2 No (ref) 
Yes 
Insurance Baseline 5 Medicare 
Medicaid 
Private 
Insurance 
Other 
None 
Case Manager Baseline 2 No (ref) 
Yes 
Education Baseline 4 High School 
diploma (ref) 
Some college 
College degree 
Graduate 
degree 
Mode of Transmission Baseline 4 Heterosexual 
(ref) 
MSM 
IDU 
NIR/NRR 
Delayed entry into Care Baseline 2 < 3 months 
(ref) 
≥ 3 months  
Weight Baseline Continuous Continuous 
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Height Baseline Continuous Continuous 
ART/HAART use  2 No (ref) 
Yes 
CD4 count  Baseline Continuous  Continuous 
CD4 count (outcome) Overtime1 Continuous Continuous  
HIV-RNA viral load Baseline Continuous Continuous 
1The date that each variable is measured, after diagnosis of HIV, will be recorded as well.  
AIM 2:  To determine whether the association between BMI at diagnosis and a 
marker of disease progression (CD4 T cell count) over time differ by gender. 
To determine whether AIM 1 varies by race and sex, investigators will use the 
same variables that will be used to analyze AIM 1, but will stratify the results by the 
gender (Male and Female). The following formula will be used to calculate BMI:  
(weight in lbs. * 703)/(height in inches2). Gender differences in demographic and clinical 
characteristics will be assessed by using Pearson’s χ2, Fisher’s exact, or Kruskal-Wallis 
tests for categorical variables and t-test for continuous variables. A change between two 
test results is considered significant if it is a 30% change in absolute CD4 count or 3 
percentage point change in CD4 percentage. A mixed regression analysis will be 
conducted to determine whether the mean values of the marker of HIV progression (CD4 
count) are different over-time between BMI categories vary by gender, after adjusting for 
the following confounding variables:  age, race, marital status, smoking, alcohol use, 
drug use, insurance, case manager, education, mode of transmission, delayed entry into 
care and HAART use. Tukey’s multiple comparisons test will be used to determine which 
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BMI categories’ mean values, if any, are different from each other. A loess fitting will be 
used if the data appears to be non-linear. Graphical comparisons will also be performed. 
Table 3.2:  Independent variables for AIM 2  
Variables Date Levels  Categories 
HIV seroconversion/diagnosis Baseline Date Date 
Race/Ethnicity Baseline 4 White  
Black 
Hispanic 
Other 
Gender Baseline 2 Male  
Female 
Age Baseline 5 <20 
21-29 (ref) 
30-39 
40-49 
50-59 
≥60 
Marital Status Baseline 4 Single (ref) 
Married 
Divorced 
Widowed 
Smoking Status Baseline 2 No (ref) 
Yes 
Alcohol Use Baseline 2 No (ref) 
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Yes 
Drug Use Baseline 2 No (ref) 
Yes 
Insurance Baseline 5 Medicare 
Medicaid 
Private 
Insurance 
Other 
None 
Case Manager Baseline 2 No (ref) 
Yes 
Education Baseline 4 High School 
diploma (ref) 
Some college 
College degree 
Graduate 
degree 
Mode of Transmission Baseline 4 Heterosexual 
(ref) 
MSM 
IDU 
NIR/NRR 
Delayed entry into Care Baseline 2 < 3 months 
(ref) 
≥ 3 months  
Weight Baseline Continuous Continuous 
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Height Baseline Continuous Continuous 
ART/HAART use  2 No (ref) 
Yes 
CD4 count  Baseline Continuous Continuous 
CD4 count  Overtime1 Continuous Continuous  
HIV-RNA viral load Baseline Continuous Continuous 
1The date that each variable is measured, after diagnosis of HIV, will be recorded as well.  
 
AIM 3:  To determine the association between BMI at diagnosis and markers of 
cardiovascular disease risk (Fasting blood glucose, HDL and LDL, and SBP and 
DBP) over time. 
In order to determine the association between baseline BMI and markers of HIV, 
the following formula will be used to calculate BMI:  (weight in lbs. * 703)/(height in 
inches2). Descriptive analyses will be conducted as well. Statistical analyses will 
Pearson’s χ2, Fisher’s exact, or Kruskal-Wallis tests for categorical variables and t-test for 
continuous variables. A mixed regression analysis will be conducted to determine 
whether the mean values of the markers of cardiovascular disease risk are different over-
time between BMI categories, after adjusting for the following confounding variables: 
race, gender, age, marital status, smoking, alcohol use, drug use, insurance, case 
manager, education, mode of transmission, delayed entry into care, baseline CD4 count, 
baseline VL, baseline fasting blood glucose, baseline HDL, baseline LDL, baseline SBP 
and DBP, and HAART use. These variables were chosen due to their association between 
both BMI and the HIV disease. Tukey’s multiple comparisons test will be used to 
determine which BMI categories’ mean values, if any, are different from each other. A 
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loess fitting will be used if the data appears to be non-linear. Graphical comparisons will 
also be performed. 
Those on cholesterol, hypertension and diabetic medications before diagnosis will 
be excluded from the analysis. 
Table 3.3:  Independent variables for AIM 3  
Variables Date Levels  Categories 
HIV seroconversion/diagnosis Baseline Date Date 
Race/Ethnicity Baseline 4 White (ref) 
Black 
Hispanic 
Other 
Gender Baseline 2 Male (ref) 
Female 
Age Baseline 5 <20 
21-29 (ref) 
30-39 
40-49 
50-59 
≥60 
Marital Status Baseline 4 Single (ref) 
Married 
Divorced 
Widowed 
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Smoking Status Baseline 2 No (ref) 
Yes 
Alcohol Use Baseline 2 No (ref) 
Yes 
Drug Use Baseline 2 No (ref) 
Yes 
Insurance Baseline 5 Medicare 
Medicaid 
Private 
Insurance 
Other 
None 
Case Manager Baseline 2 No (ref) 
Yes 
Education Baseline 4 High School 
diploma (ref) 
Some college 
College degree 
Graduate 
degree 
Mode of Transmission Baseline 4 Heterosexual 
(ref) 
MSM 
IDU 
 
Weight Baseline Continuous Continuous 
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Height Baseline Continuous Continuous 
ART/HAART use  2 No (ref) 
Yes 
HDL and LDL Baseline Continuous Continuous 
Blood Pressure (Systolic and 
Diastolic) 
Baseline Continuous Continuous 
Fasting blood glucose Baseline Continuous Continuous 
HDL and LDL Overtime1 Continuous Continuous 
Blood Pressure (Systolic and 
Diastolic) 
Overtime1 2 Continuous  
Blood Glucose Levels 
(fasting) 
Overtime1 2 Continuous 
1The date that each variable is measured, after diagnosis of HIV, will be recorded as well.  
Data management and statistical analyses will be performed using SAS 9.2 
software. Proc mixed will be used to perform the mixed model analyses.  
Sample Size/Power Analysis 
 A power analysis was conducted using SAS Proc Power to determine sample size 
needed for each BMI category. Since each AIM will be analyzed using a mixed model 
analysis, mean values of CD4 count were used (Table 4). Compared to the other 
outcomes that will be analyzed in this dissertation, CD4 was also used since it had the 
largest standard deviation, which causes the sample size to be larger compared to smaller 
standard deviations. These numbers were averaged from previous studies reports of mean 
CD4 counts for each BMI category.17 22 23 24 25 An average from these studies were 
calculated and used in the power analysis. Alpha was set to 0.05 and power was set to 
0.80.  
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Table 3.4:  Power Analysis:  Average CD4 counts per BMI category 
BMI Category Average CD4 count 
Underweight 346 
Normal 412 
Overweight 451 
Obese 473 
 
 The power analysis determined that at least 85 HIV patients are needed in each 
group to ensure an 80% power for the study. We also determined how sample size affects 
power by computing sample size needed per group at different powers (Table 5) 
Table 3.5:  Power Analysis: Number (N) of HIV patients per BMI category needed at different 
powers 
N Per Group Power 
5 0.082 
10 0.127 
15 0.176 
20 0.228 
25 0.282 
30 0.336 
35 0.390 
40 0.442 
45 0.492 
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50 0.541 
55 0.586 
60 0.629 
65 0.668 
70 0.705 
75 0.738 
80 0.769 
85 0.796 
90 0.821 
95 0.843 
100 0.863 
105 0.881 
110 0.897 
115 0.911 
120 0.923 
125 0.933 
130 0.943 
135 0.951 
140 0.958 
145 0.964 
150 0.969 
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Protection Measures 
 All study personnel will be trained and certified in federal and state policies 
regarding the protection of human subjects’ participation in research. The human subjects 
data used in AIMS 1, 2, and 3 of this proposal are part of the University of South 
Carolina’s Ryan White Clinic program. Careful consideration will be taken to ensure the 
anonymity of study participants. No individual will be identified in any publications 
resulting from this study. To further protect patient confidentiality, the researcher will 
have access to the medical records and will be required to sign a confidentiality 
agreement and attend a USC sponsored Health Insurance Portability and Accountability 
Act (HIPPA) training. The data will be abstracted from the medical records on forms that 
will not contain any identifying information. The abstracted data will be entered into an 
electronic database which will be used in the analysis.   This investigation will pose only 
a minimal risk to the privacy of individuals, and the proposed research falls under 
Exemption 4 (AIM 1, AIM 2, and AIM 3) and Expedited Review Category 5 (AIM 1, 
AIM 2, and AIM 3). An application will be submitted to the University of South Carolina 
Institutional Review Board to approve this study (Please see Appendix A for a more 
detailed description of the Human Subjects Protection).      
Strengths and Limitations  
 There is a strong need for simple and affordable clinical criteria (i.e. BMI) to 
guide interventions such as the initiation of treatment and monitor progression of HIV. 
This is of particular importance in resource-limited countries such as the sub-Saharan 
Africa, where tests to measure CD4 and HIV-RNA viral load may not be available due to 
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expenses. Ultimately, the use of BMI could aid in reducing the onset of morbidity and 
mortality.  
 Most of the studies that have investigated this relationship have studied BMI as a 
time-dependent variable. There are limited studies that have looked at the effect of BMI 
at diagnosis as a marker to determine disease progression. However, this proposal will 
determine its association with both disease progression and cardiovascular risk due to the 
recent evidence in this field of research.  
 A limitation to this proposal is that there is potential for missing data (CD4 cell 
count, HIV-RNA viral load, HDL, LDL, TG), but it is anticipated to be minimal.  
Summary 
 This proposal outlined is significant because it looks to determine whether the use 
of BMI could be a basic prognostic factor used to measure HIV progression. Also, there 
is needed research in the field of nutrition and HIV to determine its relation as HIV 
continues to become more of a chronic disease. Dissertation committee chair, Dr. Anwar 
Merchant, has experience epidemiology, nutrition, and HIV research. Dr. Bo Cai, 
committee member, has experience in biostatistics. Dr. Kellee White, committee 
member, has experience in cardiovascular epidemiology. Dr. Wayne Duffus, committee 
member, has experience in HIV research. Combined, these investigators have an 
extensive background conducting epidemiological research and possess the 
methodological skills needed to successfully complete this study. 
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CHAPTER 4  
LONGITUDINAL ASSOCIATION BETWEEN BODY MASS INDEX (BMI) AT 
DIAGNOSIS AND HIV DISEASE PROGRESSION 
4.1  Introduction  
Malnutrition and an underweight appearance were characteristics formerly 
associated with HIV/AIDS infection and were predictive of increased mortality.21 
However, since the introduction of Highly Active Antiretroviral Therapy (HAART) in 
1996, mortality has decreased, the progression of HIV to AIDS has decelerated, and 
HAART treated individuals are experiencing weight gain and becoming more overweight 
(Body Mass Index (BMI):  25 – 29.9 kg/m2)  and obese (BMI:  ≥ 30 kg/m2).7 Some 
studies report that the obesity prevalence among the HIV population is now beginning to 
mirror the obesity epidemic among the general population.7 21   
 Pre-HAART research evaluating the association between BMI and HIV 
progression has shown either no association20 22 or that HIV-infected individuals with 
higher BMI levels are less likely to progress to AIDS and die as compared to those with 
normal weight individuals (BMI:  ≤ 24.9 kg/m2).17 24 60 However, in the post-HAART era, 
the different increased BMI categories (overweight and obese) may be differentially 
associated with disease progression and survival. For example, overweight individuals 
are reported to have a slower progression to AIDS compared to those who were obese.25 
However, obese HIV-infected individuals on HAART are reported to experience smaller 
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increases in CD4-positive T-lymphocyte count (CD4), implying that obesity may actually 
be harmful.26 27 These data suggest, that although HAART is associated with 
improvements in morbidity and mortality, progressive weight gain may additionally 
influence immune recovery, which may be reversed or slowed. However, there is a 
paucity of studies examining this relationship in the post HAART era.  
 This study is important because it was conducted in the southern United States, a 
region that suffers from one of the highest burdens of HIV-infected individuals,1 and 
overweight and obese individuals.19 Whereas previous studies have focused on mortality, 
this study investigates the longitudinal association of BMI at HIV diagnosis with disease 
progression as evaluated by CD4 counts obtained during routine medical care.  
4.2 Methods 
This is a cohort study of individuals who were receiving care at the Ryan White Clinic in 
Columbia, SC. Participants were eligible if they were diagnosed with HIV-infection from 
January 1, 1997 through December 31, 2010, were at least 18 years of age, had weight 
and height measurements within three months of HIV diagnosis, were HAART-naïve, 
and had at least one follow-up visit (within six months) after entering into care. 
Individuals who were pregnant when diagnosed and those diagnosed with AIDS at the 
initial visit were excluded. This study was approved by the University of South Carolina 
Institutional Review Board. 
The power analysis, using the difference between mean CD4 counts by BMI 
category from past research, determined that at least 85 HIV-infected individuals are 
needed in each group to ensure an 80% power for the study. Investigators abstracted de-
identified data from 409 medical records. However, since there were only 13 underweight 
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(BMI:  <18.5 kg/m2) HIV-infected individuals, this category was excluded from the 
analyses. A total of 396 individuals were included in the final analyses.  
Variables 
Outcome: The outcome evaluated for this study was CD4 cell count (cells/mm3) 
assessed over the course of medical care follow-up. CD4 cell count was used to stage 
disease and is monitored routinely by providers to determine when to start HAART and 
to assess response to treatment. CD4 cell count was used as a continuous variable in the 
analysis.  
Exposure: Body mass index at diagnosis was the main exposure variable. This 
was estimated by dividing weight in kg by height (measured at diagnosis) in m2 measured 
within three months after diagnosis. BMI was grouped into three categories:  normal (<25 
kg/m2), overweight (25-29.5 kg/m2), and obese (≥30 kg/m2).  
Time varying covariates: HIV viral load (VL) (copies/mL) was collected at 
diagnosis and monitored over the course of follow-up to assess ongoing response to 
treatment. HAART use was defined as any prescription for HIV medication over the 
course of medical care. All data was extracted from the participants’ medical records.  
Other variables recorded at baseline include age, gender, race/ethnicity, marital 
status, education, type of insurance, use of case management, alcohol use, smoking 
status, drug use, mode of transmission, and delayed entry into care (defined later). Age 
was grouped into the following five categories when included in the multivariate 
analysis:  < 20; 20-29; 30-39; 40-49; 50-59; and > 60. The following categories were 
used for race/ethnicity:  White, non-Hispanic; Black, non-Hispanic; Hispanic; Other; and 
Unknown. Education was grouped into these categories:  no high school diploma, high 
 38 
 
 
school diploma, associate degree, bachelor degree, master’s degree, or doctoral degree. 
Type of insurance was based on primary insurance and was clustered into these 
categories:  Medicare; Medicaid; Private Insurance or none (includes individuals enrolled 
in the AIDS Drug Assistance Program). Mode of transmission was grouped into four 
categories:  heterosexual, men who have sex with men (MSM), injection drug users, or 
no identified risk/no reported risk (NIR/NRR). Given that timely linkage to care has the 
potential to improve health outcomes and prevent secondary HIV transmission,61 the 
delayed entry into care variable was used as a covariate to adjust for differences between 
those who seek care early versus those who do not. Delayed entry into care was 
determined by subtracting the date of diagnosis from the date of first visit to the clinic, 
and was grouped into the two categories:  ≤3 months and ˃3 months.62 When an 
individual is diagnosed with HIV at the Ryan White Clinic, he or she is offered the 
services of a case manager to help the individual access care and other support services. 
Case management was defined as present if the individual had an assigned case manager 
and absent otherwise. We adjusted for this variable because there may be a difference in 
clinical care outcome associated with case management status. Current alcohol use, 
current smoking status, and current drug use were all assessed by yes or no questions. 
Visit number was entered into the analysis to control for time in study. Therefore, the 
first visit represented time point one, the second visit represented time point two, and so 
forth.   
Statistical Analyses 
 Demographic and clinical characteristics of the participants were compared across 
the three BMI categories, using means and standard error (SE) for continuous variables 
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and number (n) and percent (%) for categorical variables. Differences in clinical 
characteristics were compared using F-test for continuous variables and Pearson χ2, 
Fisher’s exact, or Kruskal-Wallis tests for categorical variables as appropriate.  
To determine the association between BMI at diagnosis and longitudinal CD4 cell 
counts, data were analyzed using mixed regression models. Age group, race/ethnicity, 
gender, use of case management, marital status, education, insurance type, delayed entry 
into care, mode of transmission, alcohol use, smoking status, drug use, CD4 count at 
diagnosis, and HIV VL at diagnosis and overtime were all adjusted for in the analysis 
given their relationship to BMI or HIV progression. Variables were included into the 
model sequentially:  Model 1: BMI group, age group, race/ethnicity, gender, HAART 
use, baseline CD4 count, baseline HIV VL, HIV VL over time, and mode of 
transmission; Model 2:  Model 1 + alcohol use, smoking status, and drug use; Model 3:  
Model 2 + marital status, education, and insurance type; Model 4:  Model 3 + use of case 
management; Model 5:  Model 4 + delayed entry into care. The mixed model analysis 
was also stratified by baseline VL and delayed entry into care. For this analysis, baseline 
VL was grouped into ≤100,000 copies/mL plasma and ˃100,000 copies/mL plasma. 
Adjusted CD4 count means were determined and graphed at five different time points by 
using an lsmeans statement in the mixed regression model, with tukey option to 
determine differences between BMI categories. The five time points were determined 
from quantiles obtained from a univariate analysis. Sensitivity analyses were conducted 
to test whether loss to follow-up (i.e. those with > 6 months after the last documented 
visit) impacted the results and the data were re-analyzed using the inverse-probability 
weighting method as suggested by Hernan.63 Statistical analyses were performed using 
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SAS 9.2 (SAS Institute; Cary, North Carolina). For all analyses, the α-level was set at 
0.05.  
4.3  Results 
Baseline Characteristics 
The overall study population’s mean baseline BMI was 27.4 kg/m2 (overweight) 
and mean age was 35 years. The study population were predominantly male (61.9%), 
black (74.2%), and single (61.1%); approximately 35.3% had at least a high school 
diploma,47.2% did not have insurance, 57.1% were not followed by a case manager, 
60.9% used alcohol, 54.8% smoked, 59.8% did not report drug use, 55.8% were 
heterosexual, 56.8% entered care > 3 months of diagnosis, and 88.1% were prescribed 
HAART during course of medical care (Table 1).   
BMI categories were not related to age, race/ethnicity, marital status, educational 
attainment, type of insurance, use of case manager, and HAART use. However, gender, 
alcohol use, smoking status, drug use, mode of transmission, delayed entry into care, 
CD4 count at diagnosis, and HIV VL at diagnosis were all significantly different among 
the BMI categories. Obese HIV-infected individuals were more likely to be female 
(60.4%), non-alcohol users at diagnosis (44.3%), to non-smokers (53.8%), and had the 
lowest HIV VL at baseline (4.5 logs), and the highest CD4 count at baseline (575.6 
cells/mm3) compared to the normal and overweight weight individuals.   
BMI and CD4 count over time  
The overall mean follow-up time was 6.7 years and was similar across the BMI 
categories (P=0.108). The overall mean CD4 count over time was 579.3 cells/mm3. Mean 
CD4 count was highest among obese individuals (611.2 cells/mm3), followed by 
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overweight individuals (598.1 cells/mm3) and normal weight individuals (550.5 
cells/mm3).  
Mixed models were used to determine whether CD4 count change over time was 
different among BMI categories (Table 2). After adjusting for the variables listed in 
Table 1, there were significant differences in mean CD4 count for the overweight and 
obese categories when compared to the normal weight category. Models 1 thru 5 (full 
model) were all determined to be significant. Compared with the normal weight 
individuals in the full model, the obese category had significantly larger increases in CD4 
count (5.5 cells/mm3, P = <0.001) versus the decrease in CD4 count in the overweight 
category (-2.1 cells/mm3, P = <0.001). For an example, after visit one, it is predicted that 
obese HIV-infected individuals at diagnosis will experience a 5.5 cells/mm3 increase in 
CD4 count, while obese HIV-infected individuals will experience a 2.1 decrease in CD4 
count. The results of the sensitivity analyses using the inverse-probability weighting 
method to account for loss to follow up (n=73) were qualitatively similar to the results 
presented.  
Overall, mean CD4 count increased over time. Figure 1 shows a significant 
interaction between BMI and CD4 count using the adjusted mean CD4 counts. While the 
adjusted mean CD4 count was higher at the outset for the overweight and normal weight 
groups compared to the obese category, over time the CD4 count trend increased among 
the obese and normal weight categories and decreased for the overweight category 
(Figure 1).  Figure 2 displays the differences in adjusted mean CD4 counts when 
compared to the normal weight group. The overweight category had the greatest 
difference in adjusted mean CD4 counts when compared to the normal weight group. The 
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adjusted mean CD4 counts at visit one, visit forty-two, and visit fifty-four among the 
overweight category were statistically different from the normal weight group’s adjusted 
means.  
The interaction between BMI and time among those with lower baseline VL 
values (<100,000 copies/mL plasma) were significant for the overweight and obese 
categories when compared to the normal weight individuals (time*overweight P <0.001, 
time*obese P <0.001) (Table 3). Significantly larger increases in CD4 count were seen in 
the obese category (3.3 cells/mm3) versus the overweight category who experienced 
decreases in CD4 count (-1.8 cells/mm3). Among those with higher baseline VL values 
(>100,000 copies/mL plasma), the interaction between BMI at time were significant for 
the overweight and obese categories when compared to normal weight individuals 
(time*overweight P <0.001, time*obese P <0.001). Significant decreases in CD4 count 
were seen in the obese category (-2.1 cells/mm3) and the overweight category (-1.6 
cells/mm3).   
For those individuals who entered care within three months of diagnosis, the 
interaction between BMI and time were  significant  when compared to the normal 
weight patients (time*overweight P <0.001, time*obese P  <0.001) (Table 3). 
Significantly larger increases in CD4 count were seen in the obese category (9.4 
cells/mm3) versus the overweight category that experienced decreases in CD4 count (-2.9 
cells/mm3). In those who received care after three months of diagnosis, the interactions 
between BMI and time were significant (time*overweight P <0.001, time*obese P 
<0.001) when compared to the normal weight category, with the obese category 
experiencing increases in CD4 count (2.6 cells/mm3) and the overweight category (-1.4 
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cells/mm3) experiencing decreases in CD4 cell count when compared to the normal 
weight category.  
4.4  Discussion 
Within this cohort of HIV-infected individuals, CD4 counts were highest at time 
of diagnosis among those who were obese compared to those in the overweight and 
normal weight categories. CD4 counts at diagnosis also were higher for individuals who 
entered care within three months of diagnosis and those who had lower baseline VL 
values (<100,000 copies/mL). Over time CD4 count increases were highest for the obese 
followed by the normal weight groups, but decreased for the overweight category after 
adjusting for potential confounders. Although very high BMI among HIV-infected 
individuals is associated with increased CD4 count over time, moderately high BMI was 
not. Although our results are different from recent post-HAART studies that have 
evaluated this relationship, it suggests that obesity may still be beneficial to the immune 
recovery gained from HAART.  
During the pre-HAART (before 1996) era, several studies reported that obese 
HIV-infected individuals had better survival over time.17 22 Van der Sande et al. 
discovered that the median survival time of those presenting with BMI < 16 was 
significantly lower  than the median survival time for those with a baseline BMI ≥ 22.17 
In the current investigation, we were unable to study those with BMI < 18.5 due to an 
insufficient number of underweight individuals. Shor-Posner et al. found that while CD4 
cell count over time was higher for obese individuals compared with the non-obese group 
(376 cells/mm3 vs. 364 cells/mm3), the difference was not statistically significant.22  
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A few studies found that overweight individuals have larger increases in CD4 
counts over time during the pre-HAART era.24 60Jones et al. reported a significant 
difference in CD4 count among BMI categories, with the overweight group experiencing 
larger increases in CD4 counts, followed by those of normal weight and underweight.24 
With survival as the outcome, Shuter et al. found that overweight individuals progressed 
more slowly to AIDS, and CD4 count was not independently predictive of progression to 
AIDS. 60  
Whereas the results by Van der Sande et al. and Shor-Posner et al. are similar to 
our findings, these studies were conducted during the pre-HAART era and their 
population consisted of only women24 or had a limited sample size.60 Koethe et al. 
recently investigated the relationship between BMI and HIV progression by following 
HIV-infected adults starting treatment between 1998 and 2008 (post-HAART era) and 
discovered that overweight HIV-infected individuals experienced a 12-month CD4 count 
gain in women (+ 9 cells/ uL), but not in men (-1 cells/uL), while the normal weight (-65 
cells/uL) and obese categories (-12 cells/uL) experienced a reduction.25 They suggested 
that there may be an optimal BMI range for immune recovery once on treatment for a 
year, with immune reconstitution reaching a plateau in the range of BMI 25 to 30 kg/m2. 
Crum-Cianflone et al. reported that in the HAART era, obese HIV-infected individuals 
had smaller increases in CD4 counts (+69 cells/mm3) compared to those in the 
overweight (+116 cells/mm3) and normal weight categories (+102 cells/mm3).26 Although 
previous post-HAART studies report different results, our results could be due to our 
study population being from South Carolina where high levels of HIV and obesity exist.   
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There are a few proposed clinical explanations for our results. First, leptin is a 
satiety hormone that circulates directly proportional to weight and is known to increase 
with inflammation.64 Obese individuals have a higher concentration of leptin compared to 
overweight and normal weight individuals and given HIV causes inflammation and CD4 
cells have leptin receptors and has a proliferation effect, it could explain the increase or 
higher levels of CD4 among obese individuals. Secondly, obesity is surplus of energy in 
the form of stored fat that acts to spare protein from being used as an energy source, 
which aids in preserving immune function.19 This helps to neutralize the high metabolic 
rate of HIV and could explain the protective effect of obesity on CD4 levels. Thirdly, as 
Jones et al proposed, since untreated HIV-infection is associated with weight loss, 
individuals in the normal weight category are a mixed group consisting of both 
individuals who were normal weight pre-diagnosis, and those who were overweight but 
lost weight because of HIV-infection in the period preceding their diagnosis.24 
Furthermore, individuals in the overweight category are a mixed group consisting of both 
individuals who were overweight pre-diagnosis, and those who were obese but lost 
weight because of HIV-infection. These explanations are an example of reverse causality 
and a potential confounder in all studies evaluating this question.  
To prevent the possibility of weight change being mis-classified into another BMI 
category, height and weight was collected within three months of diagnosis. If reverse 
causality is contributing to the association between BMI and HIV progression, then the 
BMI characteristics of the source population are likely important. As HIV is diagnosed at 
an earlier stage, before wasting sets in, the HIV-infected population is similar to the 
general population with respect to BMI. In our study population the mean BMI was 27.4 
 46 
 
 
kg/m2, and overweight and obesity prevalence was 30% and 26.8%, which is similar to 
the prevalence of overweight (35.4%) and obesity (31.5%) in general HIV-uninfected 
population in South Carolina.19 However, the percentages differ the population of HIV-
infected drug users in the report by Shor-Posner et al. (overweight or obese 18%),4 or 
HIV-infected predominantly Latino population attending an urban health clinic in Bronx, 
NY in the report by Shuter et al. (overweight 21.7%),60 or high risk women (history of 
injection drug use or high-risk sexual contact) in the report by Jones et al.(obesity 
18.8%).24 The characteristics of the study population in this report were similar for all 
HIV-infected individuals in the entire state of South Carolina, with respect to race (Black: 
74.2% versus 76%) and mode of transmission (MSM:  33.1% versus 37.1%).66 Given the 
similarities between our study cohort and the overall HIV-infected population in South 
Carolina, it is unlikely that reverse causality significantly impacted our results.  
There are several limitations to our study. First, the secular change of CD4 count 
is impacted as more HIV-infected individuals are prescribed HAART and medication 
efficacy has increased, which could potentially attenuate the associations.67 Second, our 
population consisted of mostly black HIV-infected individuals and the results may not be 
generalizable to other populations. Third, we were unable to make an assumption that 
included the underweight BMI category. However, past research has shown that 
underweight individuals generally have a faster progression to AIDS and death compared 
to other BMI categories.17 24 25 Fourth, the treatment variable only measured whether 
individuals received HAART throughout the course of their HIV infection. We did not 
assess time spent on HAART. Fifth, there is the possibility of residual confounding. 
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Finally, the alcohol use and drug use variables only captured whether individuals were 
socially participating in these factors and not the frequency of use. 
Our study has several strengths. First, we investigated the post-HAART 
longitudinal association between BMI at baseline and HIV progression in a southern 
state. In contrast, the majority of other studies from other regions focused on survival 
rather than continuous immune function. Second, unlike previous research, we adjusted 
for many potential confounders including delayed entry into HIV medical care and use of 
case management. Entry into HIV medical care is essential for access to antiretroviral 
therapy and facilitates the delivery of important prevention education to reduce HIV 
transmission. In addition, retention in care is necessary to monitor response to therapy. 
Therefore, adjusting for delayed entry into care is important to accurately determine the 
association between BMI and HIV progression as it relates to both. Whereas our results 
were similar to Koethe’s et al. results in regards to mean CD4 counts, they were not able 
to adjust for educational attainment or insurance type.25 The current study was able to 
gain an improved estimation of the relationship between BMI at diagnosis and CD4 count 
over time by adjusting for these variables. Third, our population of individuals with 
different stages of HIV disease, allows us to determine if the relationship under study 
exists in HIV-infected individuals with different levels of immune impairment. Fourth, 
the inverse probability weighting method used to evaluate the possible impact of loss to 
follow-up provided materially similar results to those reported. Finally, this investigation 
includes fourteen years of follow-up (i.e. those diagnosed in 1997) allowing us to assess 
CD4 count over a long period.  
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Our study results demonstrate that HIV-infected individuals who were obese at 
diagnosis had greater increases in CD4 counts over time when compared to HIV-infected 
individuals who were overweight and normal weight at diagnosis. This suggests that 
providers should pay closer attention to weight at diagnosis to predict the response to 
treatment. Additional studies are needed among different populations to support the 
conflicting results produced by studies that have evaluated this relationship. Because 
BMI at diagnosis may be an important factor in predicting disease trajectory in the post-
HAART era, other studies are needed to evaluate immune impairment of those with high 
BMI and establish a biologic basis for the observed differences. 
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Table 4.1:  Baseline characteristics of South Carolina HIV-infected individals diagnosed between 
1997 and 2010 by Body Mass Index (BMI) category.  
Characteristic Overall 
(n=396) 
Normal 
(n=171)  
Overweight 
(n=119) 
Obese 
(n=106) 
Pa 
Body Mass Index  27.4 ± 6.3 22.3 ± 1.8 27.2 ± 1.5     35.9 ± 5.2 <0.001 
Age 35.1 ± 10.6 34.5 ± 11.5 36.1 ± 9.5 34.5 ± 10.2 0.378 
Gender 
      Male 
      Female 
      Transgender 
 
245 (61.9%) 
149 (37.6%) 
2 (0.5%) 
 
126 (73.7%) 
44 (25.7%) 
1 (0.6%) 
 
78 (65.6%) 
41 (34.5%) 
 
 
41 (38.7%) 
64 (60.4%) 
1 (0.9%) 
 
 
 
<0.001 
Race 
      White, non-Hispanic 
      Black, non-Hispanic 
      Hispanic 
      Other 
      Unknown 
 
92 (23.2%) 
294 (74.2%) 
3 (0.8%) 
1 (0.3%) 
6 (1.5%) 
 
38 (22.2%)  
127 (74.3%) 
2 (1.2%) 
 
4 (2.3%) 
 
28 (23.6%) 
88 (74.0%) 
1 (0.8%) 
1 (0.8%) 
1 (0.8%) 
 
26 (24.5%) 
79 (74.5%) 
 
 
1 (1.0%) 
 
 
 
 
 
0.899 
Marital Status 
      Single 
      Married 
      Divorced 
      Widowed 
      Partnered 
      Unknown 
 
242 (61.1%) 
47 (11.9%) 
70 (17.7%) 
14 (3.5%) 
21 (5.3%) 
2 (0.5%) 
 
111 (64.9%) 
15 (8.8%) 
25 (14.6%) 
7 (4.1%) 
12 (7.0%) 
1 (0.6%) 
 
71 (59.7%) 
19 (16.0%) 
18 (15.1%) 
5 (4.2%) 
6 (5.0%) 
 
 
60 (56.6%) 
13 (12.3%) 
27 (25.5%) 
2 (1.9%) 
3 (2.8%) 
1 (0.9%) 
 
 
 
 
 
 
0.166 
Education 
      No HS Diploma     
      High School Diploma 
      Associate Degree 
      Bachelor Degree 
      Master’s Degree 
      Doctorate Degree 
      Unknown 
 
63 (35.3%) 
140 (5.8%) 
23 (6.1%) 
24 (2.3%) 
9 (0.8%) 
3 (15.9%) 
134 (33.8%) 
 
34 (19.9%) 
61 (35.6%) 
8 (4.7%) 
6 (3.5%) 
4 (2.3%) 
2 (1.2%) 
56 (32.8%) 
 
13 (10.9%) 
45 (37.8%) 
4 (3.4%) 
8 (6.7%) 
3 (2.6%) 
1 (0.8%) 
45 (37.8%) 
 
16 (15.1%) 
34 (32.1%) 
11 (10.4%) 
10 (9.4%) 
2 (1.9%) 
 
33 (31.1%) 
 
 
 
 
 
 
 
<0.001 
Insurance 
      Medicare 
      Medicaid 
      Private Insurance 
      None 
 
70 (17.7%) 
43 (10.9%) 
96 (24.2%) 
187 (47.2%) 
 
33 (19.3%) 
17 (9.9%) 
30 (17.6%) 
91 (53.2%) 
 
19 (16.0%) 
10 (8.4%) 
35 (29.4%) 
55 (46.2%) 
 
18 (17.0%) 
16 (15.1%) 
31 (29.3%) 
41 (38.7%) 
 
 
 
 
0.064 
Followed by Case Manager 
      Yes 
      No 
 
170 (42.9%) 
226 (57.1%) 
 
82 (47.9%) 
89 (52.1%) 
 
44 (37.0%) 
75 (63.0%) 
 
44 (41.5%) 
62 (58.5%) 
 
 
0.170 
Alcohol Use 
      Yes 
      No 
      Unknown 
 
241 (60.9%) 
138 (34.8%) 
17 (4.3%) 
 
117 (68.4%) 
49 (28.7%) 
5 (2.9%) 
 
73 (61.3%) 
42 (35.3%) 
4 (3.4%) 
 
51 (48.1%) 
47 (44.3%) 
8 (7.6%) 
 
 
 
0.017 
Smoking 
      Yes 
      No 
      Unknown 
  
217 (54.8%) 
162 (40.9%) 
17 (4.3%) 
 
114 (66.7%) 
52 (30.4%) 
5 (2.9%) 
 
63 (53.0%) 
53 (44.5%) 
3 (2.5%) 
 
40 (37.7%) 
57 (53.8%) 
9 (8.5%) 
 
 
 
<0.001 
Drug Use 
      Yes 
      No 
      Unknown 
 
141 (35.6%) 
237 (59.8%) 
17 (4.6%) 
 
72 (42.1%) 
94 (55.0%) 
5 (2.9%) 
 
44 (37.0%) 
71 (59.7%) 
4 (3.3%) 
 
25 (23.6%) 
72 (67.9%) 
9 (8.5%) 
 
 
 
0.010 
Delayed entry into care 
      <3 months 
      ≥3 months 
 
171 (43.2%) 
225 (56.8%) 
 
78 (45.6%) 
93 (54.4%) 
 
39 (32.8%) 
80 (67.2%) 
 
54 (50.9%) 
52 (49.1%) 
 
 
0.016 
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HAART use 
      Yes 
      No 
 
365 (88.1%) 
31 (11.9%) 
 
161 (94.2%) 
10 (5.8%) 
 
109 (91.6%) 
10 (8.4%) 
 
95 (89.6%) 
11 (10.4%) 
 
 
0.109 
CD4 count at diagnosis 499.3 ±  255.2 448.4 ± 229.1 498.4 ± 231.1 575.6 ± 296.2 0.019 
 
Log HIV VL at diagnosis 4.1 ± 0.9 4.2 ± 0.9 4.2 ± 0.9 3.8 ± 0.9 <0.001 
Abbreviations:  MSM, men who have sex with men; IDU, injecting drug user; NIR/NRR, no 
identified/reported risk factor 
NOTE:  Mean and standard deviation are shown for Body mass Index, Age, CD4 count at diagnosis, HIV 
VL at diagnosis. 
- Normal (≤ 24.9 kg/m2), Overweight (25.0-29.9 kg/m2), Obese (≥ 30.0 kg/m2). Underweight individuals 
were excluded because numbers were too few for meaningful analysis.  
a  Comparison between baseline BMI strata 
**Insurance – None:  No insurance/ADAP Program 
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Table 4.2: Mixed Model Analysis of the association between Body 
Mass Index (BMI) and CD4 count among HIV-infected individuals 
diagnosed in South Carolina between 1997 and 2010.  
Model Parameter 
Estimate 
Standard 
Error (SE) 
Pb 
Model 1 
   Time 
   BMI  
       Obese 
       Overweight 
       Normal 
   BMI*time 
       time*Obese 
       time*Overweight 
       time*Normal 
 
4.9  
 
20.8  
124.2  
* 
 
0.8  
-7.3  
* 
 
0.002 
 
0.07 
0.07 
* 
 
0.004  
0.004 
* 
 
<0.001 
 
<0.001 
<0.001 
* 
 
<0.001 
<0.001 
* 
Model 2 
   Time 
   BMI  
       Obese 
       Overweight 
       Normal 
   BMI*time 
       time*Obese 
       time*Overweight 
       time*Normal 
 
4.9 
 
6.2 
120.8 
* 
 
0.8 
-7.5  
* 
 
0.003 
 
0.07 
0.07 
* 
 
0.004 
0.004 
* 
 
<0.001 
 
<0.001 
<0.001 
* 
 
<0.001 
<0.001 
* 
Model 3 
   Time 
   BMI  
       Obese 
       Overweight 
       Normal 
   BMI*time 
       time*Obese 
       time*Overweight 
       time*Normal 
 
4.9 
 
-7.5 
107.8 
* 
 
0.5 
-7.2 
* 
 
0.003 
 
 0.08 
 0.07 
 
* 
0.005 
0.005 
* 
 
<0.001 
 
<0.001 
<0.001 
* 
 
<0.001 
<0.001 
* 
Model 4 
   Time 
   BMI  
       Obese 
       Overweight 
       Normal 
   BMI*time 
       time*Obese 
       time*Overweight 
       time*Normal 
 
5.0 
 
-14.5 
101.8 
* 
 
0.6 
-7.2  
* 
 
0.003 
 
 0.08 
 0.07 
* 
 
 0.005 
 0.004 
* 
 
<0.001 
 
<0.001 
<0.001 
* 
 
<0.001 
<0.001 
 
Model 5 (Full model) 
   Time  
   BMI  
       Obese 
       Overweight 
       Normal 
   BMI*time 
       time*Obese 
       time*Overweight 
       time*Normal 
 
5.1 
 
-13.3 
106.7  
* 
 
0.4 
-7.2  
* 
 
0.003 
 
0.08 
0.07 
* 
 
0.005 
0.004 
* 
 
<0.001 
 
<0.001 
<0.001 
* 
 
<0.001 
<0.001 
* 
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Abbreviations:  SE, standard error 
NOTE: * Normal BMI category - reference group. The parameter estimates 
represent the difference in the adjusted mean CD4 count by BMI category. Those 
overweight has higher mean CD4 counts. b Comparison between baseline BMI 
categories. 
- Normal (≤ 24.9 kg/m2), Overweight (25.0-29.9 kg/m2), Obese (≥ 30.0 kg/m2) 
- Underweight individuals were excluded because numbers were too few for 
meaningful analysis.  
- Model 1  includes BMI, baseline CD4 count, baseline VL, viral load over time, 
age,   gender, race, mode of transmission and treatment.  
- Model 2 includes Model 1 + alcohol, smoking, and drug use. 
- Model 3 includes Model 2 + marital status, education, and type of insurance 
- Model 4 includes Model 3 + case management 
- Model 5 includes Model 4 + delayed entry into care 
 
Table 4.3:  Mixed Model Analysis of the association between Body Mass Index (BMI) and CD4 
count stratified by Baseline VL and Delayed entry into care among HIV-infected individuals in 
South Carolina diagnosed between 1997 and 2010.  
Model Parameter 
Estimate (SE)- 
Baseline VL < 
100,000 
Parameter 
Estimate (SE)- 
Baseline VL > 
100,000 
Parameter 
Estimate (SE)- 
Delayed entry 
into care < 3 
months 
Parameter 
Estimate (SE)- 
Delayed entry 
into care > 3 
months 
Model 5 (Full model) 
        Time 
            BMI  
              Obese 
              Overweight 
              Normal 
        Time*BMI 
              time*Obese 
              time*Overweight 
              time*Normal 
 
4.0 (0.003) a  
 
-18.6 (0.08) a 
119.0 (0.08) a 
* 
 
-0.7 (0.4) a 
-5.8 (0.5) a 
* 
 
5.3 (0.006) a 
 
63.4 (0.4) a 
-97.8 (0.4) a 
* 
 
-7.4 (0.01) a 
-6.9 (0.008) a 
* 
 
2.4 (0.004) a 
 
-30.1 (0.2) a 
-9.5 (0.2) a 
* 
 
7.0 (0.008) a 
-5.3 (0.009) a 
* 
 
6.5 (0.003) a 
 
-33.1 (0.1) a 
74.3 (0.08) a 
* 
 
-3.9 (0.006) a 
-7.9 (0.005) a 
* 
Abbreviations:  SE, standard error; VL, viral load 
a p-value <0.001 
Normal (≤ 24.9 kg/m2), Overweight (25.0-29.9 kg/m2), Obese (≥ 30.0 kg/m2) 
*Normal BMI category was used as the reference category.  
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Figure 4.1:  Adjusted CD4 count means by Body Mass Index (BMI) category 
      
 
Figure 4.2:  Differences in adjusted CD4 count means by Body Mass Index (BMI) category 
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CHAPTER 5 
 
LONGITUDINAL ASSOCIATION OF THE INTERACTION OF GENDER AND 
BODY MASS INDEX (BMI) ON HIV DISEASE PROGRESSION 
 
5.1  Introduction 
Evidence to support an association between gender and HIV progression has 
varied. Some studies have found no association between gender and HIV progression, 
reporting that progression to AIDS was similar between men and women as was the risk 
of developing a CD4 cell count below 200 cells/mm3 and the risk of dying of AIDS.11 68 
However, other studies have reported differences in CD4 count by gender.8 14-16 25 69 Pre-
HAART, progression to AIDS and to death was marginally slower in women than in 
men, suggesting higher CD4 cell counts offer no significance.15 After HAART initiation, 
women had higher CD4 counts and the difference in CD4 count between men and women 
increased over time.8 14 16 25 69 Some studies report that women were more likely to 
experience an HIV/AIDS-related event compared to men and had an increased risk of 
death even after adjustment for HAART use.16 However, a recent study reported that 
post-HAART women have lower risks of HIV-AIDS-related events such as AIDS 
dementia, tuberculosis and Karposi’s sarcoma.8 While gender differences in HIV 
progression could be due to disparities in access to care, adherence, or retention, other 
factors such as BMI may play a greater role in explaining the difference.  
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Earlier studies that have assessed the relationship between BMI and HIV 
progression have produced mixed results. Pre-HAART research has shown either no 
association20 22 or that HIV-infected individuals with higher BMI levels are less likely to 
progress to AIDS and die as compared to those individuals with normal weight (BMI:  ≤ 
24.9 kg/m2).17 24 60 However, in the post-HAART era, the overweight and obese 
categories may be differentially associated with disease progression and survival. It is 
unclear whether this association is different in females and males. While the calculation 
of BMI is not gender specific, the immune response to weight can be gender specific and 
could explain the difference in immunological response to HIV, treatment, and disease 
progression between men and women.70 
This study is essential since it was conducted in the southern United States, an 
area that suffers from one of the highest burdens of HIV-infected individuals,1 and 
overweight and obese individuals.19 It investigates the gender differences in the 
longitudinal association of BMI at HIV diagnosis with disease progression as evaluated 
by CD4 counts obtained during routine medical care. To our knowledge, this is the first 
study to determine whether the association between BMI and HIV progression differs by 
gender.  
5.2  Methods 
Study Participants 
 Individuals included in this cohort study received care at the Ryan White Clinic in 
Columbia, SC. Participants were eligible if they were diagnosed with HIV-infection from 
January 1, 1997 through December 31, 2010, were at least 18 years of age, had weight 
and height measurements within three months of HIV diagnosis, were HAART-naïve, 
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and had at least one follow-up visit (within six months) after entering into care. Pregnant 
individuals and those diagnosed with AIDS at the initial visit were excluded. This study 
was approved by the University of South Carolina Institutional Review Board. 
The power analysis, using the difference between mean CD4 counts by BMI 
category from past research, determined that at least 85 HIV-infected individuals are 
needed in each group to ensure an 80% power for the study. Investigators abstracted de-
identified data from 409 medical records. However, since there were only 13 underweight 
(BMI:  <18.5 kg/m2) HIV-infected individuals and 2 transgendered HIV-infected 
individuals, they were excluded from the analyses. A total of 394 individuals were 
included in the final analyses. 
Variables 
Outcome: CD4 cell count (cells/mm3) was the outcome evaluated for this study 
and was assessed over the course of medical care follow-up. CD4 cell count was used to 
stage disease and is examined routinely by providers to determine when to initiate 
HAART and to assess response to treatment. CD4 cell count was used as a continuous 
variable in the analysis.  
Exposure: Body mass index at diagnosis and gender were the main exposure 
variables. BMI was estimated by dividing weight in kg by height (measured at diagnosis) 
in m2 measured within three months after diagnosis, and was grouped into three 
categories:  normal (<25 kg/m2), overweight (25-29.5 kg/m2), and obese (≥30 kg/m2). 
Gender was grouped as male and female.  
Time varying covariates: HIV viral load (VL) (copies/mL) was collected at 
diagnosis and monitored over the course of follow-up to assess ongoing response to 
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treatment. HAART use was defined as any prescription for HIV medication over the 
course of medical care. All data was extracted from the participants’ medical records.  
Other variables recorded at baseline include age, race/ethnicity, marital status, 
education, type of insurance, use of case management, alcohol use, smoking status, drug 
use, mode of transmission, and delayed entry into care (defined later). Age was grouped 
into the following five categories when included in the multivariate analysis:  < 20; 20-
29; 30-39; 40-49; 50-59; and > 60. The following categories were used for race/ethnicity:  
White, non-Hispanic; Black, non-Hispanic; Hispanic; Other; and Unknown. Education 
was grouped into these categories:  no high school diploma, high school diploma, 
associate degree, bachelor degree, master’s degree, or doctoral degree. Type of insurance 
was based on primary insurance and was clustered into these categories:  Medicare; 
Medicaid; Private Insurance or none (includes individuals enrolled in the AIDS Drug 
Assistance Program). Mode of transmission was grouped into four categories:  
heterosexual, men who have sex with men (MSM), injection drug users, or no identified 
risk/no reported risk (NIR/NRR). Given that timely linkage to care has the potential to 
improve health outcomes and prevent secondary HIV transmission,61 the delayed entry 
into care variable was used as a covariate to adjust for differences between those who 
seek care early versus those who do not. Delayed entry into care was determined by 
subtracting the date of diagnosis from the date of first visit to the clinic, and was grouped 
into the two categories:  ≤3 months and ˃3 months.62 When an individual is diagnosed 
with HIV at the Ryan White Clinic, he or she is offered the services of a case manager to 
help the individual access care and other support services. Case management was defined 
as present if the individual had an assigned case manager and absent otherwise. We 
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adjusted for this variable because there may be a difference in clinical care outcome 
associated with case management status. Current alcohol use, current smoking status, and 
current drug use were all assessed by yes or no questions. Visit number was entered into 
the analysis to control for time in study and was measured in months. Therefore, the first 
visit represented time point one, the second visit represented time point two, and so forth.   
Statistical Analyses 
 Demographic and clinical characteristics of the participants were compared across 
the two gender categories, using means and standard error (SE) for continuous variables 
and number (n) and percent (%) for categorical variables. Differences in clinical 
characteristics were compared using t-test for continuous variables and Pearson χ2, 
Fisher’s exact, or Kruskal-Wallis tests for categorical variables as appropriate.  
To determine the effects of BMI at diagnosis and gender on longitudinal CD4 cell 
counts, data were analyzed using mixed regression models and were stratified by gender. 
Age group, race/ethnicity, use of case management, marital status, education, insurance 
type, delayed entry into care, mode of transmission, alcohol use, smoking status, drug 
use, CD4 count at diagnosis, and HIV VL at diagnosis and overtime were all adjusted for 
in the analysis given their relationship to BMI or HIV progression. The mixed model 
analysis was also stratified by baseline VL and delayed entry into care. For this analysis, 
baseline VL was grouped into ≤100,000 copies/mL plasma and ˃100,000 copies/mL 
plasma. Adjusted CD4 count means were determined and graphed at five different time 
points by using an lsmeans statement in the mixed regression model, with tukey option to 
determine differences between BMI categories by gender. The five time points were 
determined from quantiles obtained from a univariate analysis. Sensitivity analyses were 
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conducted to test whether loss to follow-up (i.e. those with > 6 months after the last 
documented visit) impacted the results and the data were re-analyzed using the inverse-
probability weighting method as suggested by Robins et al.63 Statistical analyses were 
performed using SAS 9.2 (SAS Institute; Cary, North Carolina). For all analyses, the α-
level was set at 0.05.  
5.3  Results 
The study population’s mean BMI was 27.4 kg/m2 and was higher in females 
(30.1 kg/m2) than in males (25.8 kg/m2). Gender was not related to age, race, educational 
attainment, use of case manager, smoking, and delayed entry into care. However, BMI, 
marital status, insurance, alcohol use, drug use, mode of transmission, HAART use, CD4 
count at diagnosis, and HIV viral load at diagnosis were all significantly different among 
the gender categories. Females were more likely to be older (35.3 years of age), to be 
overweight (43.0% versus 16.8%), receive care after three months of diagnosis (57.7% 
versus 56.3%) have a higher overall mean CD4 count at diagnosis (551.4 cells/mm3), and 
a lower log HIV viral load at diagnosis (8.7 logs) compared to males.  
BMI and CD4 count (longitudinal) 
Follow-up time was similar across gender (P=0.074), although females (7.5 years) 
had a marginally higher follow-up time compared to males (6.6 years). CD4 count mean 
was higher in females (517.3 cells/mm3) than in males (473.6 cells/mm3).  
A mixed model was analyzed to determine whether CD4 count change over time 
is different among BMI between males and females (Table 2). There were significant 
differences in mean CD4 count for the overweight and obese categories when compared 
to the normal weight category among males and females. Among males, compared with 
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the normal weight individuals in the full model, the obese category had significantly 
larger increases in CD4 count (6.1 cells/mm3, P = <0.001) versus the overweight 
category (0.5 cells/mm3, P = <0.001). Among females, compared with the normal weight 
individuals in the full model, the obese category had significantly larger increases in CD4 
count (4.9 cells/mm3, P = <0.001) versus the significant decrease in CD4 count in the 
overweight category (-2.9 cells/mm3, P = <0.001). For an example, after visit one, it is 
predicted that obese HIV-infected females at diagnosis will experience a 4.9 cells/mm3 
increase in CD4 count, while overweight HIV-infected females will experience a 2.9 
decrease in CD4 count.  The obese males had larger increases in CD4 count over time 
compared to obese females, but the overweight females had larger decreases in CD4 
count over time compared to the increase in overweight males. The results of the 
sensitivity analyses using the inverse-probability weighting method to account for loss to 
follow up (n=73) were qualitatively similar to the results presented. 
Overall, mean CD4 count increased over time for females and males. Figure 1 
shows a significant interaction between BMI and CD4 count using the adjusted mean 
CD4 counts. The adjusted mean CD4 count was higher at the outset for the obese males, 
followed by overweight females and males. Over time the CD4 count trend increased 
among all groups, except the overweight female category, which decreased over time 
(Figure 1).  The second graph (B) displays the differences in adjusted mean CD4 counts 
when compared to the normal weight group. The overweight males and females had the 
greatest difference in adjusted mean CD4 counts when compared to the normal weight 
males and females. The adjusted mean CD4 counts at each visit were not statistically 
different from the normal weight group’s adjusted means.  
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The mixed model analysis among those with lower baseline VL values (<100,000 
copies/mL plasma) showed a significant change in CD4 count over time between BMI 
categories among males and females (Table 3). In males, significantly larger increases in 
CD4 count were seen in the obese category (3.8 cells/mm3) versus the overweight 
category who experienced decreases in CD4 count (-1.2 cells/mm3). In females, 
significantly larger increases in CD4 count were seen in the obese category (3.4 
cells/mm3) versus the overweight category who experienced decreases in CD4 count (-3.8 
cells/mm3). Among those with higher baseline VL values (>100,000 copies/mL plasma), 
significant changes in CD4 count over time was seen between BMI categories among 
males and females. In males, significantly larger decreases in CD4 count were seen in the 
obese category (-2.6 cells/mm3) and the overweight category (-0.5 cells/mm3). In 
females, significant decreases in CD4 count were seen in the obese category (-13.2 
cells/mm3) and the overweight category (-2.0 cells/mm3).    
For those individuals who entered care within three months of diagnosis, 
significant changes in CD4 count over time was seen in the BMI categories when 
compared to the normal weight patients among males and females (Table 3). In males, 
significant increases in CD4 count were seen in the obese category (1.2 cells/mm3) versus 
the overweight category that experienced decreases in CD4 count (-0.3 cells/mm3). In 
females, significantly larger increases in CD4 count were seen in the obese category (3.3 
cells/mm3) versus the overweight category that experienced decreases in CD4 count (-4.0 
cells/mm3). In those who received care after three months of diagnosis, significant 
changes in CD4 count over time was seen in the BMI categories when compared to the 
normal weight patients among males and females. In males, significantly larger increases 
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in CD4 count were seen in the obese category (2.6 cells/mm3) versus the overweight 
category that experienced decreases in CD4 count (-10.3 cells/mm3). In females, 
significant increases in CD4 count were seen in the obese (9.9 cells/mm3) versus the 
overweight category that experienced decreases in CD4 count (-2.3 cells/mm3) when 
compared to the normal weight category.  
5.4  Discussion 
This cohort of HIV–infected individuals experienced CD4 counts that were 
highest at time of diagnosis among obese females, followed by overweight females and 
obese males. Over time, CD4 count increases were highest for the obese males, followed 
by the obese females and overweight males, but decreased for overweight females. While 
high BMI among HIV-infected individuals is linked to increased CD4 count over time in 
males and females, moderately high BMI was not, particularly among females. This 
implies that the immune recovery gained from HAART and the effect is different among 
males and females.  
Several studies reported that obese HIV-infected individuals had better survival 
over time.22 24 60 Shor-Posner et al. study population included men (n=82) and women 
(n=43) and had a higher proportion of obese men (69.6%) than obese females (30%). 
They discovered that CD4 cell count over time was higher for obese individuals 
compared with the non-obese group (376 cells/mm3 vs. 364 cells/mm3), although not 
statistically significant.22 Another study included only women (n=871) and reported a 
significant difference in CD4 count among BMI categories, with the overweight group 
experiencing larger increases in CD4 counts, followed by those of normal weight and 
underweight.24 The results of this study were different from the women in our study. 
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Shuter et al. study population included men (n=103) and women (86) and also had a 
higher proportion of women (32.5%) who were overweight compared to men (12.6%). 
They learned that overweight individuals progressed more slowly to AIDS, and CD4 
count was not independently predictive of progression to AIDS. 60 
A post-HAART study recently investigated the relationship between BMI and 
HIV progression by following HIV-infected men (n=712) and women (n=203) starting 
treatment between 1998 and 2008 and discovered that overweight HIV-infected 
individuals experienced a 12-month CD4 count gain in women (+ 9 cells/ uL), but not in 
men (-1 cells/uL), while the normal weight (-65 cells/uL) and obese categories (-12 
cells/uL) experienced a reduction.25 In addition, they learned that the interaction of sex 
and BMI did not appear to be an important determinant of CD4 count change (P=0.16), 
which is different from our study results. Our study determined that the association 
between BMI and CD4 count change over time is distinct in men and women, with a 
significantly larger increase in CD4 counts in obese men compared to obese women.  
One researcher proposed that there may be an ideal BMI range for immune 
recovery once on treatment for a year, with immune reconstitution reaching a plateau in 
the range of BMI 25 to 30 kg/m.2 25 This could explain why overweight individuals are 
experiencing higher mean absolute CD4 counts compared to obese individuals. A recent 
post-HAART study included men (n=1556) and women (n=126) and reported that, obese 
HIV-infected individuals had smaller increases in CD4 counts (+69 cells/mm3) compared 
to those in the overweight (+116 cells/mm3) and normal weight categories (+102 
cells/mm3).54  
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The following explanations could validate our results. First, hormones, 
particularly estrogen, may be responsible for fat distribution and storage in non-HIV 
populations and could explain the difference in immune response in HIV-infected men 
and women.70 71 Secondly, women reportedly have healthier behaviors and higher 
adherence rates to medication, which could explain higher overall mean CD4 count.8 The 
women in our study had a higher CD4 count and lower VL at diagnosis compared to 
men, but were less likely to be on HAART. However, overweight males who had a 
baseline VL ≤100,000 and who entered care within three months of diagnosis had higher 
increases in CD4 count compared to overweight females. Thirdly, leptin is a satiety 
hormone that circulates directly proportional to weight.64 Leptin is also known to increase 
with inflammation. Obese individuals have a higher concentration of leptin compared to 
overweight and normal weight individuals. Given HIV causes inflammation and CD4 
cells have leptin receptors and has a proliferation effect, it could explain the increase or 
higher levels of CD4 among obese individuals. Fourthly, obesity is surplus of energy in 
the form of stored fat. 19 Obesity spares protein from being used as an energy source, 
which aids in maintaining immune function and helps to offset the high metabolic rate of 
HIV. This could explain the protective effect of obesity on CD4 levels. Lastly, some 
proclaim that since untreated HIV-infection is associated with weight loss, individuals in 
the normal weight category are a mixed group consisting of both individuals who were 
normal weight pre-diagnosis, and those who were overweight but lost weight because of 
HIV-infection in the period preceding their diagnosis.24 This is an example of reverse 
causality and a potential confounder in all studies evaluating this question.  
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To avoid weight change being mis-classified into another BMI category, height 
and weight was collected within three months of diagnosis. If reverse causality is 
contributing to the association between BMI and HIV progression, then the BMI 
characteristics of the source population are likely important. As HIV is diagnosed at an 
earlier stage, before wasting sets in, the HIV-infected population is similar to the general 
population with respect to BMI. In our study population the mean BMI was 27.4 kg/m2, 
and overweight and obesity prevalence was 30% and 26.8%, which is similar to the 
prevalence of overweight (35.4%) and obesity (31.5%) in general HIV-uninfected 
population in South Carolina.19 Similar characteristics were discovered between our 
study population and all HIV-infected individuals in the entire state of South Carolina, 
with respect to race (Black: 74.2% versus 76%) and mode of transmission (MSM:  33.1% 
versus 37.1%).66 Given the comparisons between our study cohort and the overall HIV-
infected population in South Carolina, reverse causality most likely did not influence our 
results.  
Several limitations may have impacted our results. First, we were unable to make 
an hypothesis that included the underweight BMI category. Nonetheless, past research 
has shown that underweight individuals normally have a faster progression to AIDS and 
death compared to other BMI categories.17 24 25 Second, the treatment variable only 
measured whether individuals received HAART throughout the course of their HIV 
infection. We did not assess time spent on HAART.  Third, the secular change of CD4 
count is impacted as more HIV-infected individuals are prescribed HAART and 
medication efficacy has increased, which could potentially attenuate the associations.68 
Fourth, our population consisted of mostly black HIV-infected individuals and the results 
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may not be generalizable to other populations. Fifth, the alcohol use and drug use 
variables only captured whether individuals were socially participating in these factors 
and not the frequency of use. Sixth, we did not collect any information on gynecological 
factors (i.e. contraception use, menopause status) that could potentially confound our 
results. Finally, there is the likelihood of residual confounding such as measurement error 
of a particular variable. 
Our study has several strengths. First, we examined the post-HAART longitudinal 
association between BMI at baseline and HIV progression in a southern state. In contrast, 
the majority of other studies from other regions focused on survival rather than 
continuous immune function. Second, unlike previous research, we adjusted for many 
potential confounders including delayed entry into HIV medical care and use of case 
management. Entry into HIV medical care is essential for access to antiretroviral therapy 
and facilitates the delivery of important prevention education to reduce HIV transmission. 
In addition, retention in care is necessary to monitor response to therapy. Therefore, 
adjusting for delayed entry into care is important to accurately determine the association 
between BMI and HIV progression as it relates to both. Whereas our results were similar 
to Koethe’s et al. results in regards to mean CD4 counts, they were not able to adjust for 
educational attainment or insurance type.25 The current study was able to gain an 
improved estimation of the relationship between BMI at diagnosis and CD4 count over 
time by adjusting for these variables. Third, our population of individuals with different 
stages of HIV disease, allows us to determine if the relationship under study exists in 
HIV-infected individuals with different levels of immune impairment. Fourth, this 
investigation includes fourteen years of follow-up (i.e. those diagnosed in 1997) allowing 
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us to assess CD4 count over a long period. Finally, the inverse probability weighting 
method used to evaluate the possible impact of loss to follow-up provided materially 
similar results to those reported.  
Our study demonstrated that male HIV-infected individuals who were obese at 
diagnosis had greater increases in CD4 counts over time when compared to female HIV-
infected individuals who were obese at diagnosis. Although obese males experience 
higher CD4 count increases over time, obese females who seek care early and have a 
lower at diagnosis VL experience a better prognosis of HIV. This suggests that 
innovative strategies are needed to determine ways to improve differences in immune 
response between genders. Future studies should evaluate differences in hormonal 
activity on CD4 counts over time between genders, especially among females, to learn 
more about the difference in progression between males and females.   
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Table 5.1:  Baseline characteristics of South Carolina HIV-infected 
individals diagnosed between 1997 and 2010 by Gender.  
 Overall (n=394) Pa 
Characteristic Male 
(n=245) 
Female 
(n=149) 
 
Age 34.9 ± 10.4 35.3 ± 10.9 0.684 
Body Mass Index 
      Obese 
      Overweight 
      Normal 
 
126 (51.4%) 
41 (16.8%) 
78 (31.8%) 
 
44 (29.5%) 
64 (43.0%) 
41 (27.5%) 
 
 
 
<0.001 
Race 
      White 
      Black 
      Hispanic 
      Other 
 
65 (26.5%) 
172 (70.2%) 
3 (1.2%) 
5 (2.0%) 
 
25 (16.8%) 
122 (81.9%) 
 
2 (1.3%) 
 
 
 
 
0.090 
Marital Status 
      Single 
      Married 
      Divorced 
      Widowed 
      Partnered 
      Unknown 
 
163 (66.5%) 
19 (7.8%) 
36 (14.7%) 
6 (2.4%) 
20 (8.2%) 
1 (0.4%) 
 
78 (52.3%) 
28 (18.8%) 
34 (22.8%) 
8 (5.4%) 
 
1 (0.7%) 
 
 
 
 
 
 
<0.001 
Education 
      No HS Diploma       
      High School Diploma 
      Associate Degree 
      Bachelor Degree 
      Master’s Degree 
      Doctorate Degree 
      Unknown 
 
31 (12.7%) 
100 (40.8%) 
11 (4.5%) 
16 (6.5%) 
5 (2.0%) 
2 (0.8%) 
80 (32.7%) 
 
31 (20.8%) 
40 (26.8%) 
12 (8.0%) 
8 (5.4%) 
4 (2.7%) 
1 (0.7%) 
53 (35.6%) 
 
 
 
 
 
 
 
0.071 
Insurance 
      Medicare 
      Medicaid 
      Private Insurance 
      None 
 
41 (16.7%) 
9 (3.7%) 
58 (23.7%) 
137 (55.9%) 
 
29 (19.5%) 
34 (22.8%) 
37 (24.8%) 
49 (32.9%) 
 
 
 
 
<0.001 
Followed by Case Manager 
      Yes 
      No 
 
105 (42.9%) 
140 (57.1%) 
 
65 (43.6%) 
84 (56.4%) 
 
 
0.882 
Alcohol Use 
      Yes 
      No 
      Unknown 
 
179 (73.0%) 
58 (23.7%) 
8 (3.3%) 
 
62 (41.6%) 
78 (52.4%) 
9 (6.0%) 
 
 
 
<0.001 
Smoking 
      Yes 
      No 
      Unknown 
 
145 (59.2%) 
91 (37.1%) 
9 (3.7%) 
 
72 (48.3%) 
69 (46.3%) 
8 (5.4%) 
 
 
 
0.104 
Drug Use 
      Yes 
      No 
      Unknown 
 
99 (40.4%) 
137 (55.9%) 
9 (3.7%) 
 
42 (28.2%) 
98 (65.8%) 
9 (6.0%) 
 
 
 
0.039 
Mode of Transmission 
      Heterosexual 
      MSM 
 
92 (37.5%) 
123 (50.2%) 
 
135 (90.6%) 
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      IDU 
      NIR/NRR 
16 (6.6%) 
14 (5.7%) 
4 (2.7%) 
10 (6.7%) 
 
<0.001 
Delayed entry into care 
      < than 3 months 
      > than 3 months 
 
107 (43.7%) 
138 (56.3%) 
 
63 (42.3%) 
86 (57.7%) 
 
 
0.787 
HAART use 
      Yes 
      No 
 
223 (91.0%) 
22 (9.0%) 
 
124 (83.2%) 
25 (16.8%) 
 
 
0.021 
CD4 count at diagnosis 465.6 ± 218.4 551.4 ± 297.2  
<0.001 
Log HIV Viral Load at 
diagnosis 
 
4.3 ± 0.9 
 
3.8 ± 1.0 
 
<0.001 
NOTE:  Mean and standard deviation are shown for Body mass Index, Age,  
CD4 count at diagnosis, HIV Viral Load at diagnosis; Transgender was not  
included in the table.  
Normal (≤ 24.9 kg/m2), Overweight (25.0-29.9 kg/m2), Obese (≥ 30.0 kg/m2) 
a  Comparison between baseline BMI and gender stratas  
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Table 5.2:  Mixed Model Analysis of the association between Body Mass 
Index (BMI) and CD4 count among HIV-infected individuals diagnosed in 
South Carolina between 1997 and 2010 stratified by Gender.  
Model Parameter 
Estimate  
Standard 
Error (SEa) 
Pb 
MALES 
   Full Model  
      Time   
      BMI  
          Obese 
          Overweight 
          Normal 
      time*BMI 
          time*Obese 
          time*Overweight 
          time*Normal 
 
 
5.2 
 
-4.9  
43.1 
* 
 
0.4 
-5.7 
* 
 
 
0.003 
 
0.1 
0.09 
* 
 
0.007  
0.006 
* 
 
 
<0.001 
 
<0.001 
<0.001 
* 
 
<0.001 
<0.001 
* 
FEMALES 
   Full Model  
      Time   
      BMI  
          Obese 
          Overweight 
          Normal 
      time*BMI 
          time*Obese 
          time*Overweight 
          time*Normal 
 
 
3.0 
 
-123.9 
94.5 
* 
 
1.9  
-5.9  
* 
 
 
0.005 
 
0.1  
0.1 
* 
 
0.008  
0.007 
* 
 
 
<0.001 
 
<0.001 
<0.001 
* 
 
<0.001 
<0.001 
* 
NOTE: * Normal BMI category was used as the reference group. The parameter estimates 
represent the difference in the adjusted mean CD4 count by BMI category. Those 
overweight has higher mean CD4 counts. 
Normal (≤ 24.9 kg/m2), Overweight (25.0-29.9 kg/m2), Obese (≥ 30.0 kg/m2) 
a SE=Standard Error 
b Comparison between baseline BMI categories  
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Table 5.3:  Mixed Model Analysis of the association between Body Mass Index (BMI) and CD4 count 
stratified by Baseline VL and Delayed entry into care among HIV-infected individuals in South 
Carolina diagnosed between 1997 and 2010 by Gender.  
Model Parameter 
Estimate (SE)- 
Baseline VL < 
100,000 
Parameter 
Estimate (SE)- 
Baseline VL > 
100,000 
Parameter 
Estimate (SE)- 
Delayed entry 
into care < 3 
months 
Parameter 
Estimate (SE)- 
Delayed entry 
into care > 3 
months 
Model 5 (Full model) 
    Males   
        Time 
            BMI  
              Obese 
              Overweight 
              Normal 
        Time*BMI 
              time*Obese 
              time*Overweight 
              time*Normal 
    Females   
        Time 
            BMI  
              Obese 
              Overweight 
              Normal 
        Time*BMI 
              time*Obese 
              time*Overweight 
              time*Normal 
 
 
4.6 (0.004) a  
 
-46.9 (0.1) a 
117.7 (0.1) a 
* 
 
-0.8 (0.009) a 
-5.8 (0.006) a 
* 
 
3.9 (0.005) a 
 
32.9 (0.1) a 
-96.2 (0.2) a 
* 
 
-0.5 (0.008) a 
-6.1 (0.007) a 
* 
 
 
5.8 (0.006) a 
 
154.7 (1.2) a 
510.7 (0.4) a 
* 
 
-8.4 (0.02) a 
-6.3 (0.01) a 
* 
 
-5.8 (0.06) a 
 
-42.8 (1.4) a 
-114.4 (1.6) a 
* 
 
-7.4 (0.08) a 
3.8 (0.06) a 
* 
 
 
7.5 (0.004) a 
 
-1.7 (0.1) a 
64.0 (0.1) a 
* 
 
-6.3 (0.01) a 
-7.8 (0.006) a 
* 
 
2.4 (0.005) a 
 
-137.1 (0.2) a 
32.4 (0.2) a 
* 
 
0.9 (0.009) a 
-6.4 (0.008) a 
* 
 
 
2.2 (0.004) a 
 
-205.7 (0.4) a 
256.3 (0.4) a 
* 
 
0.4 (0.01) a 
-12.5 (0.03) a 
* 
 
2.0 (0.01) a 
 
-431.8 (2.5) a 
-135.6 (2.7) a 
* 
 
7.9 (0.02) a 
-4.3 (0.02) a 
* 
Abbreviations:  SE, standard error; VL, viral load 
Normal (≤ 24.9 kg/m2), Overweight (25.0-29.9 kg/m2), Obese (≥ 30.0 kg/m2) 
a p-value <0.001 
*Normal BMI category was used as the reference category. 
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Figure 5.1:  Adjusted CD4 count means by BMI and Gender Categories 
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CHAPTER 6 
 
LONGITUDINAL CHANGES IN CARDIOVASCULAR DISEASE RISK 
MARKERS AND THEIR ASSOCIATION WITH BODY MASS INDEX (BMI) IN 
HIV-INFECTED INDIVIDUALS 
 
6.1  Introduction 
Once highly active antiretroviral treatment (HAART) was initiated, the wasting 
syndrome became a decreased presence among HIV-infected population. One of the 
complications related to HAART was weight gain, which lead to an increased prevalence 
of overweight and obesity among HIV-infected individuals.1 21 Approximately two out of 
every three adults are overweight (i.e. BMI = 25-29.9) and more than one-third of adults 
are obese (i.e. BMI ≥30), with non-Hispanic blacks having the highest age-adjusted rates 
of obesity in the US.19 South Carolina (30.8%) is one of thirteen states that have a 
prevalence of obesity equal to or greater than 30% in the general population. Some 
studies have reported a lower prevalence of obesity among HIV-infected populations 
versus the general population,52 53 whereas others have reported a higher prevalence.24 30 
Although the effect of HAART in causing obesity in HIV-infected patients may result in 
a moderately slower progression to AIDS due to the survival gain afforded by elevated 
BMI,24 an increase in non-AIDS related outcomes, including metabolic abnormalities, 
have developed and has led to increased risk of morbidity and mortality.54   
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Abdominal obesity, hyperlipidemia, hypertension, and insulin resistance are 
examples of these abnormalities.55 One of the primary causes for the rising prevalence of 
the abnormalities is the rising prevalence of overweight and obesity in non-HIV and 
HIV-infected individuals, leading to an increased chance of developing adverse 
cardiovascular outcomes such as myocardial infarction and stroke. 21 As suggested by 
some studies, inflammation caused by the long-term effects of HIV or HAART may also 
play a greater role in causing these outcomes among HIV-infected individuals, 
particularly because inflammation is known to be predictive of cardiovascular disease 
(CVD) outcomes among non-HIV populations.72 73 
One study reported that BMI was useful in predicting cardiovascular disease 
(CVD) risk among their HIV population.28 Given the increased risk of CVD outcomes in 
non-HIV obese individuals, it is important to study this association among various HIV-
infected populations and determine if this association is differentially affected between 
BMI categories. The importance of this study is that it was conducted in the southern 
United States, a region that has the highest prevalence of HIV-infected individuals,1 
overweight and obese individuals, and cardiovascular disease.19 A limited number of 
studies have evaluated the changes in metabolic abnormalities over time by BMI group. 
This study investigates the longitudinal association of BMI at HIV diagnosis with 
metabolic abnormalities as evaluated by markers of cardiovascular disease (i.e. fasting 
blood glucose, high-density lipoprotein (HDL) and low-density lipoprotein (LDL), and 
systolic and diastolic blood pressure measurements) obtained during routine medical 
care.  
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6.2  Methods 
Study population and procedure 
 Individuals included in this cohort study received care at the Ryan White Clinic in 
Columbia, SC. Eligible participants were diagnosed with HIV-infection from January 1, 
1997 through December 31, 2010, were at least 18 years of age, had weight and height 
measurements within three months of HIV diagnosis, were HAART-naïve, and had at 
least one follow-up visit (within six months) after entering into care. Individuals were 
excluded if pregnant when diagnosed or diagnosed with AIDS at the initial visit. The 
University of South Carolina Institutional Review Board approved this study.  
Using the difference between mean CD4 counts by BMI category from past 
research, the power analysis determined that at least 85 HIV-infected individuals are 
needed in each group to ensure an 80% power for the study. Investigators extracted de-
identified data from 409 medical records. However, since there were only 13 underweight 
(BMI:  <18.5 kg/m2) HIV-infected individuals, this category was excluded from the 
analyses. A total of 396 individuals were included in the final analyses.  
Variables 
Outcome: Five outcomes were evaluated for this study: Fasting blood glucose 
(mg/dL), HDL (mg/dL), LDL (mg/dL), Systolic blood pressure (SBP) (mmHg), and 
Diastolic blood pressure (DBP) (mmHg) levels were assessed over the course of medical 
care follow-up. These outcomes were used to determine risk of illness and cardiovascular 
disease, and the effects of HIV alone and with HAART. Each outcome was used as a 
continuous variable in the analysis.  
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Exposure: The main exposure variable was BMI at diagnosis and was estimated 
by dividing weight in kg by height (measured at diagnosis) in m2 measured within three 
months after diagnosis. BMI was grouped into three categories:  normal (<25 kg/m2), 
overweight (25-29.5 kg/m2), and obese (≥30 kg/m2).  
Time varying covariates: CD4 cell count (cells/mm3) and HIV viral load (VL) 
(copies/mL) were collected at diagnosis and monitored over the course of follow-up to 
estimate disease stage, to determine when to start HAART, and to assess ongoing 
response to treatment. Fasting blood glucose, HDL, LDL, SBP, and DBP were also 
collected at diagnosis. HAART use and any medication prescribed for abnormalities in 
HDL/LDL, SBP/DBP measurements, and blood glucose levels were defined as any 
prescription for HIV medication, hyperlipidemia, hypertension or diabetes respectively, 
over the course of medical care. All data was extracted from the participants’ medical 
records.  
Additional variables documented at baseline include age, gender, race/ethnicity, 
marital status, education, type of insurance, use of case management, alcohol use, 
smoking status, drug use, mode of transmission, and delayed entry into care (defined 
later). Age was categorized into the following five categories when included in the 
multivariate analysis:  < 20; 20-29; 30-39; 40-49; 50-59; and > 60. The following 
categories were used for race/ethnicity:  White, non-Hispanic; Black, non-Hispanic; 
Hispanic; Other; and Unknown. Education was grouped into these categories:  no high 
school diploma, high school diploma, associate degree, bachelor degree, master’s degree, 
or doctoral degree. Type of insurance was based on primary insurance and was clustered  
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into these categories:  Medicare; Medicaid; Private Insurance or none (includes 
individuals enrolled in the AIDS Drug Assistance Program). Mode of transmission was  
grouped into four categories:  heterosexual, men who have sex with men (MSM), 
injection drug users, or no identified risk/no reported risk (NIR/NRR). Timely linkage to 
care is likely to improve health outcomes and prevent secondary HIV transmission, 61 
thus the delayed entry into care variable was added as a covariate to adjust for differences 
between those who seek care early versus those who do not. Delayed entry into care was 
determined by subtracting the date of diagnosis from the date of first visit to the clinic, 
and was categorized into two categories:  ≤3 months and ˃3 months.62 The services of a 
case manager are offered when a HIV-infected individual is referred to care and to help 
the individual access care and other support services. Case management was defined as 
present if the individual had an assigned case manager and absent otherwise. We adjusted 
for this variable because there may be a difference in clinical care outcome associated 
with case management status. Current alcohol use, current smoking status, and current 
drug use were all assessed by yes or no questions. Visit number was entered into the 
analysis to control for time in study, which was measured in months. Therefore, the first 
visit represented time point one, the second visit represented time point two, and so forth.   
Statistical Analyses 
 Demographic and clinical characteristics of the participants were compared across 
the three BMI categories, using means and standard error (SE) for continuous variables 
and number (n) and percent (%) for categorical variables. Differences in clinical 
characteristics were compared using t-test for continuous variables and Pearson χ2, 
Fisher’s exact, or Kruskal-Wallis tests for categorical variables as appropriate.  
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To determine the association between BMI at diagnosis and the five metabolic 
abnormalities, data were analyzed using mixed regression models. Age group, 
race/ethnicity, gender, use of case management, marital status, education, insurance type, 
delayed entry into care, mode of transmission, alcohol use, smoking status, drug use, 
fasting blood glucose at diagnosis, HDL and LDL at diagnosis, and SBP and DBP 
measurements at diagnosis, HAART use, other medication uses, CD4 count at diagnosis 
and overtime, and HIV VL at diagnosis and overtime were all adjusted for in the analysis 
given their relationship to BMI and/or the metabolic abnormalities. The adjusted means 
for each outcome were calculated and graphed at five different time points by using an 
lsmeans statement in the mixed regression model, with tukey option to determine 
differences between BMI categories. The five time points were determined from 
quantiles obtained from a univariate analysis. Sensitivity analyses were conducted to test 
whether loss to follow-up (i.e. those with > 6 months after the last documented visit) 
impacted the results and the data were re-analyzed using the inverse-probability 
weighting method as suggested by Robins et al.63 Statistical analyses were performed 
using SAS 9.2 (SAS Institute; Cary, North Carolina). For all analyses, the α-level was set 
at 0.05.  
6.3  Results 
Baseline Characteristics 
 The study population was considered overweight, with a 27.4 kg/m2 mean 
baseline BMI, and mean age was 35 years. This cohort was primarily male (61.9%),  
black (74.2%), and single (61.1%); approximately 35.3% had at least a high school 
diploma, 47.2% did not have insurance, 57.1% were not followed by a case manager, 
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60.9% used alcohol, 54.8% smoked, 59.8% did not report drug use, 55.8% were 
heterosexual, 56.8% entered care > 6 months of diagnosis, and 88.1% were prescribed 
HAART throughout course of medical care (Table 1).   
BMI categories were similar in regards to age, race/ethnicity, marital status, 
educational attainment, type of insurance, use of case manager, HAART use, cholesterol 
medication, blood glucose at diagnosis, HDL at diagnosis, LDL at diagnosis, SBP at 
diagnosis, and DBP at diagnosis. However, significant differences among the BMI 
categories were found in gender, alcohol use, smoking status, drug use, mode of 
transmission, delayed entry into care, CD4 count at diagnosis, HIV VL at diagnosis, 
diabetic medication, and BP medication. When compared to the normal and overweight 
HIV-infected individuals, obese HIV-infected individuals were more likely to be female 
(60.4%), non-alcohol users at diagnosis (44.3%), to be non-smokers (53.8%), and had the 
lowest HIV VL at baseline (4.5 logs), and the highest CD4 count at baseline (575.6 
cells/mm3), highest fasting blood glucose at baseline (106.6 mg/dL), highest HDL at 
baseline (49.2 mg/dL), highest SBP (130.7 mmHg), and highest DBP (83.3 mmHg).   
BMI and fasting blood glucose over time  
The overall mean follow-up time was 6.7 years and was similar across the BMI 
categories (P=0.108). The overall mean for fasting blood glucose over time was 100.3 
mg/dL. Mean fasting blood glucose was highest among obese individuals (108.8 mg/dL),  
followed by overweight individuals (101.5 mg/dL) and normal weight individuals (95.2 
mg/dL).  
Figure 1 shows a significant interaction between BMI and fasting blood glucose. 
The adjusted mean fasting blood glucose was higher at the outset for the obese category, 
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but it decreased over time and was the lowest at the end of follow-up, followed by the 
overweight and normal weight categories (Figure 1). When compared to the normal  
weight category, differences in adjusted mean fasting blood glucose were greater among 
the obese category than the overweight category.  
Mixed models were used to determine whether the main effect of fasting blood 
glucose and fasting blood glucose change over time was different among BMI categories 
(Table 2). After adjusting for the variables listed in Table 1, there were statistically 
significant differences in mean fasting blood glucose for the overweight and obese 
categories when compared to the normal weight category. Compared with the normal 
weight individuals in the full model, the obese category had significant decreases in 
fasting blood glucose levels (-0.2 mg/dL, P = <0.001) versus the increase in fasting blood 
glucose in the overweight category (0.1 mg/dL, P = <0.001). For an example, after visit 
one, it is predicted that obese HIV-infected individuals at diagnosis will experience a 0.2 
mg/dL decrease in fasting blood glucose, while overweight HIV-infected individuals will 
experience a 0.1 increase in fasting blood glucose.  
BMI and HDL over time  
The overall mean for HDL over time was 48.1 mg/dL. Mean HDL was highest 
among overweight individuals (50.6 mg/dL), followed by obese individuals (47.7 mg/dL) 
and normal weight individuals (46.5 mg/dL).  
Overall, HDL decreased slightly over time. Figure 2 shows a significant 
interaction using between BMI and the adjusted mean HDL. While the HDL was higher 
at the outset for the overweight and normal weight groups compared to the obese 
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category, over time the obese group had a larger increase in HDL compared to the 
overweight and normal weight categories (Figure 2).  When compared to the normal  
weight category, differences in adjusted mean HDL were greater among the obese 
category than the overweight category.  
Mixed models were used to determine whether the main effect of HDL and HDL 
change over time was different among BMI categories (Table 2). After adjusting for the 
variables listed in Table 1, there were statistically significant differences in mean HDL 
for the overweight and obese categories when compared to the normal weight category. 
Compared with the normal weight individuals in the full model, the obese (0.4 mg/dL, P 
= <0.001) and overweight categories (0.26 mg/dL, P = <0.001) had significant increases 
in HDL levels. For an example, after visit one, it is predicted that obese HIV-infected 
individuals at diagnosis will experience a 0.4 mg/dL increase in HDL, while overweight 
HIV-infected individuals will experience a 0.26 increase in HDL.  
BMI and LDL over time  
The overall mean for LDL over time was 110.5 mg/dL. Mean LDL was highest 
among overweight individuals (116.1 mg/dL), followed by obese individuals (113.7 
mg/dL) and normal weight individuals (104.8 mg/dL).  
Overall, LDL decreased over time. Figure 3 shows a significant interaction 
between BMI and the adjusted mean LDL. The overweight category had a higher LDL at 
the outset and had the largest decrease in LDL over time, followed by the obese and  
normal weight categories (Figure 3). When compared to the normal weight category, 
differences in adjusted mean LDL were greater among the overweight category than the 
obese category.  
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Mixed models were used to determine whether the main effect of LDL and LDL 
change over time was different among BMI categories (Table 2). After adjusting for the  
variables listed in Table 1, there were statistically significant differences in mean LDL 
for the overweight and obese categories when compared to the normal weight category. 
Compared with the normal weight individuals in the full model, the obese (-1.0 mg/dL, P 
= <0.001) and overweight categories (-1.4 mg/dL, P = <0.001) had significant decreases 
in LDL levels. For an example, after visit one, it is predicted that obese HIV-infected 
individuals at diagnosis will experience a 1.0 mg/dL decrease in LDL, while overweight 
HIV-infected individuals will experience a 1.4 decrease in LDL.  
BMI and SBP over time  
The overall mean for SBP over time was 128.9 mg/dL. Mean SBP was highest 
among obese individuals (132.0 mg/dL), followed by overweight individuals (130.3 
mg/dL) and normal weight individuals (126.5 mg/dL).  
Figure 4 shows a significant interaction between BMI and the adjusted mean SBP. 
The adjusted mean SBP was higher at the outset and remained the highest for the 
overweight category. Both the overweight and obese categories adjusted mean SBP 
decreased over time, compared to the increase in the normal weight category (Figure 4). 
When compared to the normal weight category, differences in adjusted mean SBP were 
greater among the obese category than the overweight category.  
Mixed models were used to determine whether the main effect of SBP and SBP 
change over time was different among BMI categories (Table 2). After adjusting for the 
variables listed in Table 1, there were statistically significant differences in mean SBP for 
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the overweight and obese categories when compared to the normal weight category. 
Compared with the normal weight individuals in the full model, the obese (-1.96 mg/dL,  
P = <0.001) and overweight categories (0.96 mg/dL, P = <0.001) had significant 
decreases in SBP levels. For an example, after visit one, it is predicted that obese HIV-
infected individuals at diagnosis will experience a 1.96 mg/dL increase in SBP, while 
overweight HIV-infected individuals will experience a 0.96 increase in SBP.  
BMI and DBP over time  
The overall mean for DBP over time was 81.6 mg/dL. Mean DBP was highest 
among obese individuals (84.2 mg/dL), followed by overweight individuals (82.1 mg/dL) 
and normal weight individuals (79.9 mg/dL).  
Figure 5 shows a significant interaction between BMI and DBP. The adjusted 
mean DBP was slightly higher at the outset for the normal category, followed by the 
obese and overweight categories (Figure 5). However over time, the normal weight 
category had a larger decrease in DBP, while the overweight and obese categories 
experienced a slight decrease. When compared to the normal weight category, differences 
in adjusted mean DBP were roughly the same among the obese category and the 
overweight category.    
Mixed models were used to determine whether the main effect of DBP and DBP 
change over time was different among BMI categories (Table 2). After adjusting for the 
variables listed in Table 1, there were statistically significant differences in mean DBP 
for the overweight and obese categories when compared to the normal weight category. 
Compared with the normal weight individuals in the full model, the obese category had 
no change in DBP levels (0.0 mg/dL, P = <0.001) versus the slight decrease in DBP in 
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the overweight category (-0.1 md/dL, P = <0.001). For an example, after visit one, it is 
predicted that obese HIV-infected individuals at diagnosis will experience relatively no 
change in DBP, while overweight HIV-infected individuals will experience a 0.1 
decrease in DBP.  
The mixed regression analysis results of the interaction between BMI category 
and HAART use on CD4 count over time are listed in Table 3. Obese HIV-infected 
individuals on HAART have significantly larger increases in fasting blood glucose (P = 
<0.001) and HDL (P = <0.001), and significantly larger decreases in LDL (P = <0.001) 
and SBP (P = <0.001) compared to overweight-HIV infected individual on HAART. 
Overweight HIV-infected individuals on HAART have larger decreases in DBP (P = 
<0.001) compared to obese HIV-infected individuals on HAART. The results of the 
sensitivity analyses using the inverse-probability weighting method to account for loss to 
follow up (n=73) were qualitatively similar to the results presented. 
6.4  Discussion 
The prevalence of overweight and obesity was considered high within this cohort, 
with nearly 57% being overweight and obese. Fasting blood glucose, HDL, and blood 
pressure levels were highest at time of diagnosis among those who were obese compared 
to those in the overweight and normal weight categories. Over time, the obese category 
had larger decreases in fasting blood glucose and SBP, and larger increases in HDL 
compared to the overweight and normal weight categories. The overweight category had  
larger decreases in LDL when compared to the obese and normal weight categories.  
Higher BMI among HIV-infected individuals is associated with increased CD4 count 
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over time and also appears to be protective against some cardiovascular disease risk 
markers.  
Obesity is known to be one of the causes of increased glucose levels, which can 
result in the development of diabetes.19 Other risk factors include race, age, physical 
inactivity, and family history of diabetes. Studies have shown that the incidence of 
diabetes increases with cumulative exposure to HAART,41 particularly protease 
inhibitors, and that the HIV-infected individuals  tend to have a greater chance for the 
development of diabetes morbidity when compared to HIV naïve patients.42 Evidence has 
shown that HIV itself causes lipodystrophy, which can cause abnormally high levels of 
blood glucose.74 One study reported an overall glucose mean of 87 mg/dL among their 
cohort of HIV-infected individuals and stated that higher BMI was associated with higher 
glucose concentrations.6 In contrast, our study had a higher overall mean of fasting blood 
glucose (100.3 mg/dL) and had an overweight population, compared to the normal weight 
population seen in the El Sadr et al. study. Additionally, our study evaluated fasting 
blood glucose over time by looking at the difference between BMI categories. We 
showed that while the obese category had a higher decrease in fasting blood glucose over 
time compared to the increase among the overweight category, they both are significantly 
lower than the normal weight category. Therefore, this population behaves dissimilar to 
the non-HIV infected individuals where higher BMIs are associated with higher glucose 
levels.  
Morbidity related to HDL and LDL levels are also associated with obesity,56 
although one study reported no association with LDL and that the negative association 
between BMI and HDL levels could be explained by insulin resistance.75 While this may 
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be true, this association is slightly different among HIV-infected individuals. El Sadr et 
al. reports an overall HDL mean of 37 mg/dL and an overall LDL mean of 98.3 mg/dL,  
and only found a significant association between BMI and LDL.6 Another study reported 
that 44.7% of their population had low HDL-C levels (<40 mg/dL), an overall LDL mean 
of 107.3, a negative significant association with BMI, and that low HDL-C levels were 
associated with antiretroviral therapy.42 Our study had higher overall means for HDL and 
LDL compared to their study. We also adjusted for glucose levels in the mixed regression 
analyses and found significantly different associations between BMI and the lipid profiles 
(HDL and LDL). Unlike non-HIV infected individuals, our study found that at a positive 
association between the obese and overweight groups with HDL, and a negative 
association between the obese and overweight group with LDL.  
Increased blood pressure is associated with the risk factors that affect both lipid 
levels and blood glucose levels, such as obesity among non-HIV infected individuals.57 
Overweight and obese individuals have higher systolic and DBP levels. Among HIV-
infected individuals, traditional risk factors are also associated with increased blood 
pressure.36 Most studies report a prevalence of hypertension among HIV-infected 
individuals to be between 25%-35% versus thirty-six percent of our population took 
blood pressure medication for hypertension over the course of follow-up.35-39 Some 
studies have stated that HAART may induce hypertension through hardening of the 
vessel walls,37 39 however others report minimal effects. 36 38 In our study, those on 
HAART had a small decrease in SBP (-2.1 ± 0.1) and an increase in DBP (7.7 ± 0.4). The 
obese individuals in our study had a higher overall mean for systolic and DBP, and larger 
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increases in SBP. Both the obese and overweight DBP levels were roughly the same over 
time.  
The results of our study could be validated by several justifications. First, it has 
been reported that obesity is associated with improved outcomes and survival in patients 
on hemodialysis, pneumonia, heart transplant, renal failure and liver cirrhosis.75 
Therefore, the immune recovery afforded to HIV-infected individuals with higher BMI 
have with CD4 count over time could explain why obese individuals have larger 
increases in fasting blood glucose and HDL. Secondly, a potential confounder in all 
studies evaluating this question is the association between weight loss and untreated HIV-
infection is called reverse causality. An example of reverse causality is when the normal 
weight category consist of individuals who were normal weight pre-diagnosis, and those 
who were overweight but lost weight because of HIV-infection in the period preceding 
their diagnosis, or when obese category includes individuals who lost weight before their 
diagnosis and were considered overweight at diagnosis.24 
To prevent the possibility of reverse causality affecting the validity of our results, 
height and weight was collected within three months of diagnosis. If reverse causality is 
contributing to the association between BMI and cardiovascular disease risk markers, 
then the BMI characteristics of the source population are likely important. As HIV is 
diagnosed at an earlier stage, before wasting sets in, the HIV-infected population is 
similar to the general population with respect to BMI. In our study population the mean 
BMI was 27.4 kg/m2, and overweight and obesity prevalence was 30% and 26.8%, which  
is similar to the prevalence of overweight (35.4%) and obesity (31.5%) in general HIV-
uninfected population in South Carolina.19 The characteristics of the study population in 
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this report were similar for all HIV-infected individuals in the entire state of South 
Carolina, with respect to race (Black: 74.2% versus 76%) and mode of transmission  
(MSM:  33.1% versus 37.1%).62 Given the similarities between our study cohort and the 
overall HIV-infected population in South Carolina, it is unlikely that reverse causality 
significantly impacted our results.  
This study has some limitations. First, the treatment variables only measured 
whether individuals received HAART, cholesterol medication, diabetic medication, or 
blood pressure medication throughout the course of their HIV infection. We did not 
assess time spent on these medications. Second, we were unable to make an assumption 
that included the underweight BMI category. However, past research has shown that 
underweight individuals generally are not associated with increased chances of diabetes, 
hypertension or dyslipidemia compared to other BMI categories, although some have 
reported that underweight may be associated with risk of developing these diseases. 
Third, the alcohol use and drug use variables only captured whether individuals were 
socially participating in these factors and not the frequency of use. Fourth, our population 
consisted of mostly black HIV-infected individuals and the results may not be 
generalizable to other populations. Finally, there is the possibility of residual 
confounding such as measurement error of a CD4.  
This study has several strengths. First, we explored the post-HAART longitudinal 
association between BMI at baseline and cardiovascular risk markers in a southern state. 
Second, unlike previous research, we adjusted for many potential confounders including 
delayed entry into HIV medical care and use of case management. Entry into HIV 
medical care is imperative for access to antiretroviral therapy and facilitates the delivery 
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of important prevention education to reduce HIV transmission. In addition, retention in 
care is critical to monitor response to therapy. Finally, this investigation includes fourteen  
years of follow-up (i.e. those diagnosed in 1997) allowing us to assess the cardiovascular 
disease risk markers over a long period. Third, our population of individuals with 
different stages of HIV disease, allows us to determine if the relationship under study 
exists in HIV-infected individuals with different levels of immune impairment.  
The results of this study revealed that HIV-infected individuals who were obese at 
diagnosis had greater decreases in fasting blood glucose and larger increases in HDL over 
time when compared to HIV-infected individuals who were overweight at diagnosis. 
Although higher BMI is associated with improved cardiovascular risk markers among 
this HIV-population, providers should monitor weight at diagnosis due to its correlation 
with inflammation. Because BMI plays an important role in causing metabolic 
abnormalities in non-HIV populations and because BMI at diagnosis may be an important 
factor in predicting the effects of HIV and treatment on metabolic abnormalities, 
additional studies are needed to evaluate markers of inflammation over time, particularly 
among different HIV-infected populations.  
 
 
 
 
 
 
 90 
 
 
Table 6.1:  Baseline characteristics of South Carolina HIV positive individals diagnosed between 
1997 and 2010 by Body Mass Index (BMI) category.  
Characteristic Overall 
(n=396) 
Normal 
(n=171) 
Overweight 
(n=119) 
Obese 
(n=106) 
Pa 
Body Mass Index  27.4 ± 6.3 22.3 ± 1.8 27.2 ± 1.5 35.9 ± 5.2 <0.001 
Age 35.1 ± 10.6 34.5 ± 11.5 36.1 ± 9.5 34.5 ± 10.2 0.378 
Gender 
      Male 
      Female 
      Transgender 
 
245 (61.9%) 
149 (37.6%) 
2 (0.5%) 
 
126 (73.7%) 
44 (25.7%) 
1 (0.6%) 
 
78 (65.6%) 
41 (34.5%) 
 
 
41 (38.7%) 
64 (60.4%) 
1 (0.9%) 
 
 
 
<0.001 
Race 
      White, non-Hispanic 
      Black, non-Hispanic 
      Hispanic 
      Other 
      Unknown 
 
92 (23.2%) 
294 (74.2%) 
3 (0.8%) 
1 (0.3%) 
6 (1.5%) 
 
38 (22.2%) 
127 (74.3%) 
2 (1.2%) 
 
4 (2.3%) 
 
28 (23.6%) 
88 (74.0%) 
1 (0.8%) 
1 (0.8%) 
1 (0.8%) 
 
26 (24.5%) 
79 (74.5%) 
 
 
1 (1.0%) 
 
 
 
 
 
0.899 
Marital Status 
      Single 
      Married 
      Divorced 
      Widowed 
      Partnered 
      Unknown 
 
242 (61.1%) 
47 (11.9%) 
70 (17.7%) 
14 (3.5%) 
21 (5.3%) 
2 (0.5%) 
 
111 (64.9%) 
15 (8.8%) 
25 (14.6%) 
7 (4.1%) 
12 (7.0%) 
1 (0.6%) 
 
71 (59.7%) 
19 (16.0%) 
18 (15.1%) 
5 (4.2%) 
6 (5.0%) 
 
 
60 (56.6%) 
13 (12.3%) 
27 (25.5%) 
2 (1.9%) 
3 (2.8%) 
1 (0.9%) 
 
 
 
 
 
 
0.166 
Education 
      High School Diploma 
      Associate Degree 
      Bachelor Degree 
      Master’s Degree 
      Doctorate Degree 
      No HS Diploma 
      Unknown 
 
140 (35.3%) 
23 (5.8%) 
24 (6.1%) 
9 (2.3%) 
3 (0.8%) 
63 (15.9%) 
134 (33.8%) 
 
61 (35.6%) 
8 (4.7%) 
6 (3.5%) 
4 (2.3%) 
2 (1.2%) 
34 (19.9%) 
56 (32.8%) 
 
45 (37.8%) 
4 (3.4%) 
8 (6.7%) 
3 (2.6%) 
1 (0.8%) 
13 (10.9%) 
45 (37.8%) 
 
34 (32.1%) 
11 (10.4%) 
10 (9.4%) 
2 (1.9%) 
 
16 (15.1%) 
33 (31.1%) 
 
 
 
 
 
 
 
0.207 
Insurance 
      Medicare 
      Medicaid 
      Private Insurance 
      None 
 
70 (17.7%) 
43 (10.9%) 
96 (24.2%) 
187 (47.2%) 
 
33 (19.3%) 
17 (9.9%) 
30 (17.6%) 
91 (53.2%) 
 
19 (16.0%) 
10 (8.4%) 
35 (29.4%) 
55 (46.2%) 
 
18 (17.0%) 
16 (15.1%) 
31 (29.3%) 
41 (38.7%) 
 
 
 
 
0.064 
Followed by Case Manager 
      Yes 
      No 
 
170 (42.9%) 
226 (57.1%) 
 
82 (47.9%) 
89 (52.1%) 
 
44 (37.0%) 
75 (63.0%) 
 
44 (41.5%) 
62 (58.5%) 
 
 
0.170 
Alcohol Use 
      Yes 
      No 
      Unknown 
 
241 (60.9%) 
138 (34.8%) 
17 (4.3%) 
 
117 (68.4%) 
49 (28.7%) 
5 (2.9%) 
 
73 (61.3%) 
42 (35.3%) 
4 (3.4%) 
 
51 (48.1%) 
47 (44.3%) 
8 (7.6%) 
 
 
 
0.017 
Smoking 
      Yes 
      No 
      Unknown 
 
217 (54.8%) 
162 (40.9%) 
17 (4.3%) 
 
114 (66.7%) 
52 (30.4%) 
5 (2.9%) 
 
63 (53.0%) 
53 (44.5%) 
3 (2.5%) 
 
40 (37.7%) 
57 (53.8%) 
9 (8.5%) 
 
 
 
<0.001 
Drug Use 
      Yes 
      No 
      Unknown 
 
141 (35.6%) 
237 (59.8%) 
17 (4.6%) 
 
72 (42.1%) 
94 (55.0%) 
5 (2.9%) 
 
44 (37.0%) 
71 (59.7%) 
4 (3.3%) 
 
25 (23.6%) 
72 (67.9%) 
9 (8.5%) 
 
 
 
0.010 
Mode of Transmission 
      Heterosexual 
      MSM 
 
221 (55.8%) 
131 (33.1%) 
 
81 (47.4%) 
72 (42.1%) 
 
66 (55.5%) 
38 (31.9%) 
 
74 (69.8%) 
21 (19.8%) 
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      IDU 
      NIR/NRR 
20 (5.1%) 
24 (6.1%) 
8 (4.7%) 
10 (5.9%) 
7 (5.9%) 
8 (6.7%) 
5 (4.7%) 
6 (5.7%) 
 
0.013 
Delayed entry into care 
      <3 months 
      ≥3 months 
 
171 (43.2%) 
225 (56.8%) 
 
78 (45.6%) 
93 (54.4%) 
 
39 (32.8%) 
80 (67.2%) 
 
54 (50.9%) 
52 (49.1%) 
 
 
0.016 
HAART use 
      Yes 
      No 
 
349 (88.1%) 
47 (11.9%) 
 
161 (94.2%) 
10 (5.8%) 
 
109 (91.6%) 
10 (8.4%) 
 
95 (89.6%) 
11 (10.4%) 
 
 
0.109 
Diabetic medication 
      Yes 
      No 
 
36 (9.1%) 
360 (90.9%) 
 
11 (6.4%) 
160 (93.6%) 
 
8 (6.7%) 
111 (93.3%) 
 
17 (16.0%) 
89 (84.0%) 
 
 
0.015 
Cholesterol medication 
      Yes 
      No 
 
62 (15.7%) 
334 (84.3%) 
 
24 (14.0%) 
147 (86.0%) 
 
20 (16.8%) 
99 (83.2%) 
 
18 (17.0%) 
88 (83.0%) 
 
 
0.741 
BP medication 
      Yes 
      No 
 
143 (36.1%) 
253 (63.9%) 
 
50 (29.2%) 
121 (70.8%) 
 
44 (37.0%) 
75 (63.0%) 
 
49 (46.2%) 
57 (53.8%) 
 
 
0.016 
CD4 count at diagnosis 499.3 ±  255.2 448.4 ± 229.1 498.4 ± 231.1 575.6 ± 296.2 0.019 
 
Log HIV VL at diagnosis  
4.1 ± 0.9 
 
4.2 ± 0.9 
 
4.2 ± 0.9 
 
3.8 ± 0.9 
 
<0.001 
Fasting blood glucose at 
diagnosis 
95.8 ± 40.4 90.8 ± 27.0 92.4 ± 20.4 106.6 ± 63.8 0.102 
HDL at diagnosis 46.3 ± 19.1 46.2 ± 21.6 40.2 ± 4.4 49.2 ± 21.7 0.652 
LDL at diagnosis 113.4 ± 37.2 94.4 ± 27.6 125.4 ± 49.7 123.4 ± 35.4 0.131 
SBP at diagnosis  
126.9 ± 16.3 
 
125.7 ± 15.2 
 
124.8 ± 16.9 
 
130.7 ± 17.0 
 
0.134 
DBP at diagnosis  
81.2 ± 11.3 
 
80.2 ± 11.6 
 
80.5 ± 12.4 
 
83.3 ± 9.8 
 
0.281 
Abbreviations:  MSM, men who have sex with men; IDU, injecting drug user; NIR/NRR, no 
identified/reported risk factor; HDL, high-density lipoprotein; LDL, low-density lipoprotein; SBP, systolic 
blood pressure; DBP, diastolic blood pressure 
NOTE:  Mean and standard deviation are shown for Body mass Index, Age, CD4 count at diagnosis, HIV 
VL at diagnosis. 
- Normal (≤ 24.9 kg/m2), Overweight (25.0-29.9 kg/m2), Obese (≥ 30.0 kg/m2).  
Underweight individuals were excluded because numbers were too few for meaningful analysis. 
- Transgender was not included in the table.  
a  Comparison between baseline BMI strata 
**Insurance – None:  No insurance/ADAP Program 
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Table 6.2: Mixed Model Analysis of the association between Body Mass Index 
(BMI) and cardiovascular disease risk markers among HIV-infected 
individuals diagnosed in South Carolina between 1997-2010.   
Model Parameter 
Estimate  
Standard 
Error (SE) 
Pa 
Blood Glucose 
   Full Model  
      Time   
      BMI  
          Obese 
          Overweight 
          Normal 
      time*BMI 
          time*Obese 
          time*Overweight 
          time*Normal 
 
 
0.3 
 
10.9  
9.6 
* 
 
-0.5 
-0.3 
* 
 
 
0.007 
 
0.2 
0.2 
* 
 
0.01  
0.01 
* 
 
 
<0.001 
 
<0.001 
<0.001 
* 
 
<0.001 
<0.001 
* 
HDL 
   Full Model  
      Time   
      BMI  
          Obese 
          Overweight 
          Normal 
      time*BMI 
          time*Obese 
          time*Overweight 
          time*Normal 
 
 
0.2 
 
-4.7 
3.9 
* 
 
0.2 
0.06  
* 
 
 
0.008 
 
0.2 
0.2 
* 
 
0.01  
0.01 
* 
 
 
<0.001 
 
<0.001 
<0.001 
* 
 
<0.001 
<0.001 
* 
LDL 
   Full Model  
      Time   
      BMI  
          Obese 
          Overweight 
          Normal 
      time*BMI 
          time*Obese 
          time*Overweight 
          time*Normal 
 
 
-1.2 
 
-2.7  
3.0 
* 
 
0.2 
-0.2 
* 
 
 
0.007 
 
0.2 
0.2 
* 
 
0.01 
0.01 
* 
 
 
<0.001 
 
<0.001 
<0.001 
* 
 
<0.001 
<0.001 
* 
SBP 
   Full Model  
      Time   
      BMI  
          Obese 
          Overweight 
          Normal 
      time*BMI 
          time*Obese 
          time*Overweight 
          time*Normal 
 
 
0.04 
 
1.8 
7.0 
* 
 
-0.2  
-0.1  
* 
 
 
0.008 
 
0.2  
0.2 
* 
 
0.02  
0.01 
* 
 
 
<0.001 
 
<0.001 
<0.001 
* 
 
<0.001 
<0.001 
* 
DBP 
   Full Model  
      Time   
      BMI  
          Obese 
          Overweight 
          Normal 
 
 
-0.3 
 
-0.9 
-2.1 
* 
 
 
0.008 
 
0.2  
0.2 
* 
 
 
<0.001 
 
<0.001 
<0.001 
* 
 93 
 
 
      time*BMI 
          time*Obese 
          time*Overweight 
          time*Normal 
 
0.3 
0.2  
* 
 
0.02 
0.01 
* 
 
<0.001 
<0.001 
* 
Abbreviations:  SE, standard error; SBP, systolic blood pressure; DBP, diastolic blood 
pressure 
NOTE: * Normal BMI category - reference group. The parameter estimates represent the 
difference in the adjusted mean CD4 count by BMI category. Those overweight has higher 
mean CD4 counts. b Comparison between baseline BMI categories. 
- Normal (≤ 24.9 kg/m2), Overweight (25.0-29.9 kg/m2), Obese (≥ 30.0 kg/m2) 
- Underweight individuals were excluded because numbers were too few for meaningful 
analysis.  
- Models adjusted for, baseline CD4 count, CD4 count over time baseline VL, viral load 
over time, age, fasting blood glucose over time, HDL and LDL over time, SBP and DBP 
over time, gender, race, mode of transmission and treatment, alcohol use, smoking use, 
drug use, marital status, education, and type of insurance, case management, delayed entry 
into care, HAART use, cholesterol medication use, blood pressure medication use, and 
diabetes medication use.  
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Table 6.3:  Mixed Model Analysis of the interaction between Body Mass Index (BMI) and highly 
active antiretroviral therapy (HAART) use and its association with cardiovascular disease risk 
markers among HIV-infected individuals diagnosed in South Carolina between 1997-2010. 
Model Parameter Estimates (SE) Pa 
Blood Glucose 
      BMI*HAART use 
          Obese*Yes 
          Obese*No 
          Overweight *Yes 
          Overweight *No 
 
 
4.5 (0.5) 
* 
-6.7 (0.6) 
* 
 
 
<0.001 
* 
<0.001 
* 
HDL 
      BMI*HAART use 
          Obese*Yes 
          Obese*No 
          Overweight *Yes 
          Overweight *No 
 
 
9.9 (0.5) 
* 
-8.4 (0.6) 
* 
 
 
<0.001 
* 
<0.001 
* 
LDL 
      BMI*HAART use 
          Obese*Yes 
          Obese*No 
          Overweight *Yes 
          Overweight *No 
 
 
-18.9 (0.5) 
* 
-13.2 (0.6) 
* 
 
 
<0.001 
* 
<0.001 
* 
SBP 
      BMI*HAART use 
          Obese*Yes 
          Obese*No 
          Overweight *Yes 
          Overweight *No 
 
 
-5.5 (0.5) 
* 
1.0 (0.7) 
* 
 
 
<0.001 
* 
0.113 
* 
DBP 
      BMI*HAART use 
          Obese*Yes 
          Obese*No 
          Overweight *Yes 
          Overweight *No 
 
 
-9.3 (0.5) 
* 
-12.3 (0.7) 
* 
 
 
<0.001 
* 
<0.001 
* 
Abbreviations:  SE, standard error; SBP, systolic blood pressure; DBP, diastolic blood pressure 
NOTE: * Normal BMI category and No HAART use- reference groups.  
The parameter estimates represent the difference in the adjusted mean CD4 count by BMI category.  
Those overweight has higher mean CD4 counts. b Comparison between baseline BMI categories. 
- Normal (≤ 24.9 kg/m2), Overweight (25.0-29.9 kg/m2), Obese (≥ 30.0 kg/m2) 
- Underweight individuals were excluded because numbers were too few for meaningful analysis.  
- Models adjusted for, baseline CD4 count, CD4 count over time baseline VL, viral load over time, age, fasting blood 
glucose over time, HDL and LDL over time, SBP and DBP over time, gender, race, mode of transmission and 
treatment, alcohol use, smoking use, drug use, marital status, education, and type of insurance, case management, 
delayed entry into care, HAART use, cholesterol medication use, blood pressure medication use, and diabetes 
medication use. 
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Figure 6.1:  Adjusted fasting blood glucose means by BMI category 
 
Figure 6.2:  Differences in the adjusted fasting blood glucose means by BMI category 
 
 
 
 
Adjusted FBS Mean by BMI Category
100
105
110
115
120
125
130
Ad
jus
ted
 M
ea
n F
BS
Normal
Overweight
Obese
Normal 110.06 113.8 117.9 121.9 125.5
Overweight 118.49 118.9 119.2 119.6 119.9
Obese 119.8 118 116.1 114.2 112.6
Visit 1 Visit 14 Visit 28 Visit 42 Visit 54
Differences in Adjusted FBS Mean (Compared to Normal 
Category)
-15
-10
-5
0
5
10
15
Di
ffe
re
nc
es
 in
 A
dj
us
te
d 
M
ea
n 
FB
S
Overweight
Obese
Overweight 8.43 5.1 1.3 -2.3 -5.6
Obese 9.74 4.2 -1.8 -7.7 -12.9
Visit 1 Visit 14 Visit 28 Visit 42 Visit 54
Reference - Normal 
weight category
 96 
 
 
 
Figure 6.3:  Adjusted HDL means by BMI category 
 
 
 
Figure 6.4:  Differences in the adjusted HDL means by BMI category 
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Figure 6.5:  Adjusted LDL means by BMI category 
 
 
Figure 6.6:  Differences in the adjusted LDL means by BMI category 
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Figure 6.7:  Adjusted SBP means by BMI category     
 
 
Figure 6.8:  Differences in the adjusted SBP means by BMI category 
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Figure 6.9:  Adjusted DBP means by BMI category 
 
 
Figure 6.10:  Differences in the adjusted DBP means by BMI category 
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CONCLUSIONS 
 
 As the prevalence of overweight and obesity continues to increase among HIV-
infected individuals and as treated HIV-infected individuals continue to be plagued by 
metabolic abnormalities, additional research is needed to study this relationship among 
different HIV-infected populations and determine which factors are involved in creating 
these results. In this study, there were significant differences in CD4 count over time 
between overweight and obese individuals when compared to normal weight individuals. 
Overweight HIV-infected individuals, had larger increases in CD4 count and HDL over 
time and larger decreases in DBP over time. Obese HIV-infected individuals had larger 
increases in fasting blood glucose and SBP, which is indicative of the effects of obesity in 
causing inflammation. Female HIV-infected individuals had larger increases in CD4 
count over time compared to males. The difference between females and males could be 
explained gynecological factors such as menopause or hormone replacement therapy. 
However, this study did not assess any gynecological factors and their association with 
progression of HIV.  
 HIV data is generally non-linear and the statistical analyses chosen are very 
essential to accurately estimate differences between groups. Our study used a mixed 
model analysis which allowed us to choose the best covariance structure that fit with the 
data. Spatial power was the covariance structure fitted to the mixed model analysis 
because it allows unequal measurements of data among individuals in the study. Future 
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researchers could use non-linear mixed model analyses to obtain better estimates for this 
relationship.  
Several limitations affected our study. First, the secular change of CD4 count is 
impacted as more HIV-infected individuals are prescribed HAART and medication 
efficacy has increased, which could potentially attenuate the associations.22 Second, our 
population consisted of mostly black HIV-infected individuals and the results may not be 
generalizable to other populations. Third, we were unable to make an assumption that 
included the underweight BMI category. However, past research has shown that 
underweight individuals generally are not associated with increased chances of diabetes, 
hypertension or dyslipidemia compared to other BMI categories, although some have 
reported that underweight may be associated with risk of developing these diseases. 
Fourth, the treatment variables only measured whether individuals received HAART, 
cholesterol medication, diabetic medication, or blood pressure medication throughout the 
course of their HIV infection. We did not assess time spent on these medications.  Fifth, 
there is the possibility of residual confounding. Sixth, we did not collect any information 
on gynecological factors (i.e. contraception use, menopause status) that could potentially 
confound our results. Finally, the alcohol use and drug use variables only captured 
whether individuals were socially participating in these factors and not the frequency of 
use. 
This study has several strengths. First, we explored the post-HAART longitudinal 
association between BMI at baseline and cardiovascular risk markers in a southern state. 
Second, unlike previous research, we adjusted for many potential confounders including 
delayed entry into HIV medical care and use of case management. Entry into HIV 
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medical care is imperative for access to antiretroviral therapy and facilitates the delivery 
of important prevention education to reduce HIV transmission. In addition, retention in 
care is critical to monitor response to therapy. Finally, this investigation includes fourteen 
years of follow-up (i.e. those diagnosed in 1997) allowing us to assess the cardiovascular 
disease risk markers over a long period. Third, our population of individuals with 
different stages of HIV disease, allows us to determine if the relationship under study 
exists in HIV-infected individuals with different levels of immune impairment.  
In all, overweight and obese HIV-infected individuals have different associations 
with markers for HIV progression and cardiovascular disease risk. The causes of these 
associations are multifactorial and additional research should focus the interaction of 
these sources to understand the biological differences between overweight and obese 
HIV-infected individuals. Furthermore, this study illustrates the importance and the 
ability of BMI to predict response to treatment and potential long-term effects of the 
disease and medications.  
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Appendix A:  Protection of Human Subjects 
 
Target Population  
 
 The target population for this proposal was individuals who were HIV-positive. 
Medical records from the Ryan White Clinic were reviewed for this study. The majority 
of the clients served in the Ryan White Clinic in South Carolina were male (60%), 
African American (73%), and aged 25-44 (50.7%).35 For inclusion in the study, adults 
were at least 18 years of age, diagnosed with HIV from January 1, 1997-December 31, 
2010 in the state of South Carolina and had at least one confirmatory Western Blot, had 
weight and height measured within three months of HIV diagnosis, and those with at 
least 1 follow-up appointment after BMI was recorded at diagnosis.  HIV-positive 
individuals who are pregnant, or have taken either hypertensive, diabetic or cholesterol 
medication were excluded from this study. A total of 400 HIV-positive adults were 
included in this study. The sample size was determined using SAS 9.2 power analysis for 
ANOVA design. Given that the relationship under study is a relatively understudied area 
of research among HIV patients, this particularly study was necessary.  
Recruiting Plans  
 Recruitment of individuals for this proposal was not necessary because the 
investigators used data that was already in existence. Only de-identified data were 
collected to prevent from exposing any private information.  
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Existing Data/Samples  
 Investigators of this proposal used existing data from medical records which are 
located in Ryan White HIV/AIDS Clinic to acquire the data listed in the data abstraction 
sheet. Although the medical records contained direct identifiers, none of that information 
was collected. The data was recorded in Epi Data with the pre-approved variables listed 
on the data abstraction sheet and exported into SAS.  
Consent/Assent 
 For this proposal, consent from patients of the Ryan White Clinic was necessary 
because the investigators used data that was already in existence. Only de-identified data 
were collected to prevent from exposing any private information.  
Potential Risks 
We believe that there was minimal risk to study participants, because information 
that was collected did not contain any personal information and the investigator that 
collected the data was required to keep that information confidential. The proposed 
research fell under Exemption 4 (AIM 1, AIM 2, and AIM 3) and Expedited Review 
Category 5 (AIM 1, AIM 2, and AIM 3).  An application for this study was approved by 
the University of South Carolina, Institutional Review Board. All study personnel were 
trained and certified in federal and state policies regarding the protection of human 
subjects’ participation in research (CITI). The human subjects data used for AIMS 1, 2, 
and 3 of this proposal were part of the medical records from the Ryan White Clinic. 
Careful consideration was taken to ensure the anonymity of study participants.  No 
individual will be identified in any publications resulting from this study.  Furthermore, 
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we feel by blocking access to sensitive charts (i.e. charts from students and faculty of the 
University of South Carolina), further protected the confidentiality of all patients.  
Potential Benefits 
  There was no direct benefit to participants as a result of this study. However, the 
information obtained from this study will add to the body of scientific knowledge about 
this important area of research. This proposed research will also provide information that 
can be used to inform intervention decisions, including when to initiate therapy and 
whether monitoring BMI could be a useful marker in assessing the success of such 
therapy, particularly in resource-limited countries. Given that the rates of obesity are 
increasing among HIV patients, the results of this study could potentially help in 
understanding the factors associated with increased rates of disease progression and 
cardiovascular risk in HIV patients. Using medical records enabled this research to 
provide a more comprehensive assessment of this relationship. These findings can 
provide the framework for clinicians to develop more appropriate HIV treatment 
strategies that can ultimately allow HIV-positive individuals to live longer.  
Confidentiality  
As mandated by the state and the Institutional Review Board (IRB) of the 
University of South Carolina, authorized persons trained in the Health Insurance 
Portability and Accountability Act (HIPAA) confidentiality procedures retrieved the data. 
Study investigators were required to abide by the guidelines set forth by the state and 
school with regards to the security and confidentiality of the data. To further protect 
confidentiality, access to patient charts who were deemed sensitive (i.e. students and 
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faculty of USC) were blocked. The principle investigator was the only person collecting 
the data. Unique identifiers were created for each patient. The definition of the unique 
identifier was located within the data abstraction sheet. The unique identifier and medical 
record for each patient was recorded on the patient list file. The data file and the patient 
list file was kept in a secure location, under lock and key at the Ryan White Clinic, under 
the supervision of Shirley Patterson. Only Mrs. Patterson and I had access to the data 
files. The data was not stored on a local hard drive or network drive.  However, all data 
analysis by the investigators was conducted at University of South Carolina School of 
Public Health using password-protected computers once the data was exported to SAS.  
 
 
 
